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Abstract 
Ellipticine, an anticancer agent, has had limited clinical success due to low 
solubility and toxic side effects. To overcome these limitations, a panel of novel 
ellipticine isomers were designed and synthesised with the aim of evaluating their 
anti-cancer effects on selected cancer cell lines. A preliminary NCI 60-cell screen 
demonstrated that these isoellipticines displayed promising anti-tumour activity 
across a number of different cell types, particularly leukaemia cell lines. We 
consequently examined the effect of these derivatives in detail on the Acute Myeloid 
Leukaemia (AML) cell line, MV4-11. 
Cell cycle analyses revealed that the compounds had a range of distinctive cell 
cycle effects on MV4-11 cells. 7-Hydroxyisoellipticine showed the most promise with 
respect to cytostatic activity. We demonstrated that this compound inhibited 
proliferation of leukaemia cells by preventing cells from progressing from G2 phase. 
Our research suggests that this is mediated by an induction of reactive oxygen species 
(ROS), which in turn activates the DNA damage response pathway. More extensive 
research on the source of ROS generated by the most potent derivative, 7-formyl-10-
methylisoellipticine showed that this compounds cytotoxicity is partially mediated by 
an induction of mitochondrial derived reactive oxygen species (ROS).  
We showed that 7-formyl-10-methylisoellipticine has synergistic effects when 
used in combination with the clinically used AML drug, daunorubicin, as well as DPI, 
a Nox inhibitor. Additionally, combination experiments with other drugs served to 
give us a deeper insight into 7-formyl-10-methylisoellipticine mechanism of action.  
7-Formyl-10-methylisoellipticine also displayed promising in vivo results. 
Treatment resulted in a lack of toxicity, as mesured by body weight changes and liver 
enzyme analyses. Most importantly, 7-formyl-10-methylisoellipticine demonstrated 
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potent anti-tumour activity in the in vivo xenograft mouse model, implying the 
potential of isoellipticines as novel chemotherapeutic agents in the treatment of 
leukaemia.           
 In summary, this study provides for the first time detailed cellular information 
on the potential use of isoellipticines as chemotherapeutic agents. Our study 
documents for the first time, the therapeutic potential of an isoellipticine compound in 
a subcutaneous AML cell-derived xenograft (CDX) model. By probing the 
mechanism of action of this novel compound class we have uncovered a potential 
clinical application in the field of adjuvant therapy. We anticipate that the recent 
research on ellipticine derivatives, such as this study, will lead the development of an 
ellipticine analogue that may be employed clinically.  
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Leukaemia 
Leukaemia refers to a cancer of the blood and bone marrow and is 
characterised by the abnormal growth of white blood cells. The word leukaemia is 
derived from the greek words leukos “white” and haima “blood’. This disease 
accounts for approximately 3% of all cancers. Leukaemia can be classified as myeloid 
or lymphocytic depending on the lineage of the affected cells. Leukaemia can also be 
described as acute or chronic based on the aggressiveness of the disease. Chronic 
forms are characterised by an excessive accumulation of mature blood cells while 
acute forms are characterised by a rapid increase in immature blood cells. There are 
four main subtypes of leukaemia:  chronic lymphocytic leukaemia (CLL), chronic 
myeloid leukaemia (CML), acute lymphocytic leukaemia (ALL) and acute myeloid 
leukaemia (AML) (LLS., 2011). 
 
Acute Myeloid Leukaemia 
Acute myeloid leukaemia (AML) is a fast developing cancer of the myeloid 
lineage. It is characterised by myeloid cells that have a reduced ability to develop into 
mature cells. This failure of myeloid cell regulation leads to organ infiltration, 
bleeding and fatal infection (Estey & Döhner, 2006). In turn, a build-up of 
myeloblasts in the bone marrow, peripheral blood and the spleen also occurs which 
results in poor production of normal, healthy blood cells (Preisler & Lyman, 1977). 
AML is the most commonly occurring myeloid leukaemia; accounting for 80% of 
acute leukaemias in adults and is most commonly seen in people over 70 years of age. 
Last year the American Cancer Society reported over 20,000 new cases of AML. 
Factors that increase the risk of acquiring AML are being male, genetic mutations, 
environmental conditions and haematologic disorders (Levine & Bloomfield, 1992). 
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AML is responsible for approximately half of leukaemic deaths in children 
(Meshinchi & Arceci, 2007).  
 AML patients typically present with symptoms of fatigue, hemorrhage or 
infections and fever due to decreases in red cells, platelets, or white cells. The primary 
diagnosis of AML is based on the presence of leukaemic myeloblasts in preparations 
of peripheral blood and bone marrow stained with Giemsa-Wright. Following this 
diagnosis, the morphologic and genetic subtype must be identified. The most 
commonly used method of classification is that developed by the French–American–
British (FAB) group which divides AML into nine distinct subtypes that differ with 
respect to the particular myeloid lineage involved and the degree of leukemic-cell 
differentiation (Lowenberg et al, 1999). 
 
 FAB subtype  Name 
 M0  Undifferentiated acute myeloblastic leukemia 
 M1  Acute myeloblastic leukemia with minimal maturation 
 M2  Acute myeloblastic leukemia with maturation 
 M3  Acute promyelocytic leukemia (APL) 
 M4  Acute myelomonocytic leukemia 
 M4 eos  Acute myelomonocytic leukemia with eosinophilia 
 M5  Acute monocytic leukemia 
 M6  Acute erythroid leukemia 
 M7  Acute megakaryoblastic leukemia 
 
Table 1.1. FAB classification of Acute Myeloid Leukaemia 
 
Haematopoiesis 
Hematopoiesis is the formation of blood cellular components. Normal 
hematopoiesis is dependent upon tightly controlled and inter-related mechanisms 
regulating cell proliferation and differentiation. Hematopoiesis is initiated in the bone 
marrow by multipotent hematopoietic stem cells (HSC) (Figure 1). The HSC 
population is relatively quiescent (Bradford et al, 1997), but upon cell cycle entry it 
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gives rise to differentiating progenitor populations that undergo massive proliferative 
expansion in order to replenish the blood system and also in response to stress, such 
as injury or infection (Weissman, 2000). In hematologic malignancies normal 
hematopoiesis is interrupted by uncontrolled growth of a genetically altered stem or 
progenitor cell that retains its ability of self-renewal (Aleem & Arceci, 2015). 
 In acute myeloid leukaemia, the haematopoietic progenitor acquires 
abnormalities leading to the expansion of the leukaemic stem cell (LSC) clone 
(Bonnet & Dick, 1997). These abnormalities can develop into a fully malignant 
disease if multiple independent genetic and epigenetic alterations in oncogenes and/or 
tumour suppressor genes occur. LSCs are characterised by boundless self-renewal, 
cytoprotection and attenuated telomerase activity (Lane & Gilliland, 2010). LSCs are 
not found in the blood circulation as they primarily reside in the bone marrow 
microenvironment. This is of great importance from a clinical perspective as it 
enables them to avoid the cytotoxic effects of the chemotherapy and to re-emerge 
resulting in relapse of the disease (Lane et al, 2009).  
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Figure 1.1. Schematic representation of haematopoiesis (adapted from 
www.allthingsstemcell.com) 
 
Pathogenesis of AML 
AML is a biochemically complex heterogenous disease. The most common 
targets of AML-associated chromosomal translocations are genes that encode DNA-
binding transcription factors or the regulatory components of transcriptional 
complexes. Transformation in these cases appears to result from the generation of 
fusion proteins that interfere with the function of the wild-type protein (Lowenberg et 
al, 1999). Chromosomal aberrations are detected in 55 % of AML patients. This 
evidence suggests that leukemogenesis is a multi-step process as fusion protein 
impairment alone in myeloid differentiation is not sufficient to cause the leukaemic 
phenotype in a murine model. For this phenotype to occur, these initiating fusion 
oncogenes must be followed by complementing mutations that activate signal 
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transduction pathways resulting in increased proliferation/survival or a block in 
apoptosis/differentiation. These mutations often lead to activation of receptor tyrosine 
kinase signalling pathways, as it is in the case of FMS-like tyrosine kinase 3 FLT3 
(Döhner & Döhner, 2008).  
Genetic alterations in AML 
Approximately 300 genes have been reported to be altered in hematologic 
malignancies (Catalog of Somatic Mutations in Cancer at the Wellcome Trust Sanger 
institute). Currently, it is believed that AML arises from the cooperation between two 
classes of genetic alterations (Gilliland et al, 2004). Class I mutations provide a 
proliferation or survival advantage to blast cells. These generally include genes 
encoding key proliferative tyrosine kinase receptors, such as the FLT3 and c-KIT, as 
well as down-stream signalling regulators, such as the RAS oncogene, JAK2 and the 
IL-3 receptor family. Class II mutations that impair myeloid differentiation typically 
include mutations in the AML1, CEBPA, WT1 and PU.1 (Renneville et al, 2008). 
The interplay of deregulated proliferative and differentiation pathways has important 
consequences for the altered regulation of the cell cycle controllers. Furthermore, 
mutations in genes regulating chromatin or methylation states in hematopoietic 
progenitors are emerging as critical events in AML. These genes include the isocitrate 
dehydrogenase 1 and 2 (IDH1, IDH2), mutated in 15–30% of AML (Conway O'Brien 
et al, 2014). 
FLT3 
FLT3 it the most common genetic aberration in AML mutations. High 
expression of FLT3 is found in nearly all AML cases (Rosnet et al, 1996) and 
mutations of the FLT3 gene are detected in 30% of AML cases (Stirewalt et al, 2001). 
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FLT3 is a class III receptor tyrosine kinase (RTK) that is expressed in early 
haematopoietic cells and is important in the development of the immune system. It 
has strong structural similarities to other class III RTKs such as platelet-derived 
growth factor (PDGF). All of the class III members play important roles in 
proliferation, differentiation and survival of the haematopoietic cells. FLT3 is 
composed of an immunoglobulin-like extracellular ligand binding domain, a 
transmembrane domain, a juxtamembrane dimerization domain and a highly 
conserved intracellular kinase domain. Activation of FLT3 receptor leads to activation 
of cell signalling pathways that can promote cell survival such as Ras/MAPK, PI3K 
and JAK/STAT (Rosnet & Birnbaum, 1993).   
There are two types of FLT3 mutation involved in AML; mutation of the 
activation loop of the tyrosine kinase domain (FLT3-TKD) and the more frequently 
occurring FLT3 internal tandem duplication (FLT3-ITD) (Renneville et al, 2008), 
which is seen in 15 – 35% of AML cases (Stirewalt & Radich, 2003). FLT3-ITD 
causes ligand-independent receptor dimerization allowing phosphorylation and 
constitutive activation of the receptor resulting in cytokine-independent cellular 
proliferation (Hayakawa et al, 2000).  
 
Signal transduction implicated in AML 
Eukaryotic cells respond to their external environment by inducing signal 
transduction processes that coordinate cellular changes. Intracellular signalling 
pathways are activated when an extracellular signal is transduced into the cell through 
ligand receptor binding. The processes that follow involve a series of protein 
phosphorylation and/or dephosphorylation, protein-protein interaction and protein-
small molecule interaction (Liu & Zhao, 2004). The Raf/MEK/ERK, PI3K/AKT and 
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JAK/STAT pathways are critical in the leukomogenic process (Figure 2). These 
pathways are activated by a variety of cytokines that function to either enhance or 
inhibit hematopoiesis. As AML is a heterogeneous disease it is likely to emanate from 
multiple aberrant cascades.   
 
The PI3K/AKT pathway 
The phosphatidylinositol 3-kinase (PI3K)/AKT cascade is crucial to cell cycle 
progression, transcription, translation, differentiation, apoptosis, motility and 
metabolism (Yuan & Cantley, 2008). The relationship between deregulated PI3K 
activity and the onset of cancer is well established (Steelman et al, 2008). PI3K 
consists of an 85-kDa regulatory subunit, which contains SH2 and SH3 domains and a 
110-kDa catalytic subunit (Drexler, 1996). Phosphorylation of the p85 subunit leads 
to activation of the 110 catalytic subunit. There are three classes (I, II and III) of PI3K 
enzymes.  
The phospholipid products of PI3K activate PDK and AKT (Toker et al, 
1994), a serine/threonine protein kinase. Full AKT activation requires 
phosphorylation of Thr 308 and Ser473. It has been proposed that AKT can 
phosphorylate over 9000 proteins (Lawlor et al, 2001). It is therefore unsurprising 
that AKT can affect both cell cycle and apoptosis. Activated AKT has been reported 
to be present in over half of primary AML samples and is associated with poor 
prognosis (Kornblau et al, 2006). Phosphorylations of a range of AKT targets 
contribute to its anti-apoptotic effects. Bad was the first anti-apoptotic target to be 
identified. The interaction with this target prevents the formation of proapoptotic Bax 
homodimers (Andreeff et al, 1999). Furthermore, AKT can promote cell cycle 
progression through its interaction with a host of substrates including GSK-3 
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(Fukumoto et al, 2001). mTOR, a serine/threonine kinase is a key downstream protein 
of AKT. It regulates translation in response to nutrients/growth factors by 
phosphorylating components of the protein synthesis machinery. Integration of a 
variety of signals by mTOR assures cell cycle entry if the conditions are sufficient 
(Fingar et al, 2004). Therefore, mTOR controls enhanced production of molecules 
such as c-Myc, cyclin D1, p27
Kip1
 and retinoblastoma protein (pRb), controlling 
protein synthesis (Martin et al, 2004).  
The PI3K pathway is negatively regulated by phosphatases, most notably 
phosphatase and tensin homologue deleted on chromosome 10 (PTEN) (Steelman et 
al, 2004a). Cheong et al. found that decreased PTEN phosphorylation was present in 
approximately 75% of AML patients (Cheong et al, 2003). 
  
The JAK/STAT pathway 
The JAK/STAT pathway consists of three families of genes: the janus of 
tyrosine kinases (JAK), the signal transducers and activators of transcription (STAT) 
and the suppressors of cytokine signalling/cytokine SH2-containing family 
(CIS/SOCS) (Kisseleva et al, 2002).  JAKs are a family of large tyrosine kinases of 
which there have been four subtypes identified. JAK proteins consist of seven 
different conserved domains. Stimulation of JAKs activates STAT transcription 
activity. The STAT gene family consists of seven proteins. The structure of this 
family of proteins consists of an N-terminal oligomerization domain, a DNA-binding 
domain in the central part of the protein, a SH2 domain and a transactivation domain 
near the C terminus.  
The roles of JAK and STAT proteins have been investigated using knockout 
strains of mice (Winston et al, 1995). It is now well established that STAT3 has 
Chapter 1: General Introduction 
 10 
oncogenic properties (Danial et al, 1995). JAK3 expression is limited to 
hematopoietic cells. JAK3 knockout mice have developmental defects in lymphoid 
cells (Saharinen, 2002).  
The CIS/SOCS family of proteins serves to negatively regulate the JAK/STAT 
pathway. However, JAK/STAT are also negatively regulated by other mechanisms 
such as protein phosphatases in a similar manner to the PI3K pathway. 
  
The Ras/Raf/MEK/ERK pathway 
The Ras/Raf/MEK/ERK pathway is activated by many growth factors and 
cytokines that are important in driving proliferation and survival in hematopoietic 
cells (Steelman et al, 2004b). It has been reported that more than half of AML cases 
display constitutive activation of the Raf/MEK/ERK pathway in the absence of any 
obvious genetic mutation (Ricciardi et al, 2005). Following receptor ligation, Shc, a 
SH2 domain-containing protein, becomes associated with the C terminus of the 
growth factor receptor. Shc then recruits the GTP-exchange complex growth factor 
receptor bound-2 (Grb2)/son of sevenless exchange (Sos) proteins (Grb2/Sos) leading 
to the loading of membrane-bound Ras with GTP.
 
The result is a Ras:GTP complex, 
which recruits Raf to the membrane where it becomes activated (Minden et al, 1994). 
Mutations leading to the expression of constitutively active Ras proteins have been 
observed in approximately 30% of human cancers (Flotho et al, 1999).  
Mutations that result in increased Ras activity also disrturb the Raf/MEK/ERK 
and PI3K/AKT/mTOR cascades. Raf is a multigene family that consists of 3 
subtypes, each of which consist of three distinct functional domains. BRAF, has been 
reported to be mutated in approximately 7% of all cancers (Garnett et al, 2004). Raf 
kinases are required for phosphorylation of the mitogen-associated/extracellular 
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regulated kinase-1 (MEK1). MEK1 phosphorylates extracellular regulated kinases 1 
and 2 (ERKs 1 and 2) on specific threonine and tyrosine residues. Once activated, 
ERK1 and ERK2 serine threonine kinases go on to phosphorylate and activate a 
variety of substrates (Cardone et al, 1998). Elevated expression of ERK in AML is 
associated with a poor prognosis (Shelton et al, 2005). ERK can translocate to the 
nucleus and activate transcription factors that bind promoters of many genes, 
including genes important in stimulating the growth and survival of hematopoietic 
cells (Deng et al, 1994). Furthermore, the Raf/MEK/ERK pathway can also modulate 
the activity of many proteins involved in apoptosis including B cell leukemia-2 (Bcl-
2), Bad, and caspase 9 (Steelman et al, 2008). It is also worth noting that Raf-1 has 
many anti-apoptotic interactions that are independent of MEK and ERK (McCubrey 
et al, 2007). 
 
Figure 1.2. The key signal transduction pathways implicated in AML 
Chapter 1: General Introduction 
 12 
Cell cycle regulators in hematologic malignancies 
The cell cycle consists of a series of unidirectional ‘phases’ from G1 to M. For 
a cell to divide successfully, it must undergo each phase of the cell cycle. First, G1 
phase that results in an increased cell size in anticipation of DNA replication. This 
DNA replication occurs in the S phase. Cells then proceed through G2 phase to 
prepare to equally segregate duplicated DNA in the M phase and finally divide into 
two equal daughter cells. From G1 a cell can also exit the cell cycle and enter the sub 
G1 phase. Cells in the sub G1 phase have less than one copy of DNA and therefore 
are not viable. Cyclin-dependent kinases (cdks) control mammalian cell cycle. Cdks 
are a family of serine/threonine protein kinases that are activated by association with 
cyclin regulatory subunits (Aleem & Arceci, 2015).  
Most of the pathways that result in uncontrolled cell proliferation converge in 
a signal that activates the cell cycle. Therefore, blocking one phase of the cell cycle 
should theoretically interrupt the remaining phases and arrest proliferation. 
In the G1 phase, cdk4/cdk6 in complex with cyclin D receives signals that result in 
activation of cell cycle entry. The signalling events that follow promote the activation 
of cdk2/ cyclin E complex (Sherr & Roberts, 1999). Later in G1, the actions of this 
complex lead to the inactivation of phosphorylated retinoblastoma protein (Rb), 
which in turn releases the E2F transcription factors (Kaldis & Aleem, 2005). E2F 
promotes transcription of cyclin E, which is necessary for the G1/S transition. 
Progression through S phase is regulated by cdk2/cyclin A complex. Following this, 
cdk1/cyclin B complexes initiate mitosis. Cdk1/cyclin A complexes contribute to the 
preparation for mitosis (Edgar & Lehner, 1996).  
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Reactive Oxygen Species (ROS) 
All highly reactive oxygen derivatives can be referred to as reactive oxygen 
species (ROS). This group includes oxygen radicals such as superoxide (O2
•−
), 
hydroxyl (OH
•
), peroxyl (RO2
•
), and alkoxyl (RO
•
) as well as nonradicals that are 
either oxidising agents or are easily converted into radicals, such as hypochlorous acid 
(HOCl), singlet oxygen (
1
O2), and hydrogen peroxide (H2O2) (Woolley et al, 2013). 
The balance between oxidation and antioxidation is critical in maintaining healthy 
biological systems. The human antioxidative defense system including superoxide 
dismutase (SOD), catalase (CAT), Peroxiredoxins (Prx), glutathione peroxidase 
(GPx) and glutathione (GSH) facilitates the elimination of excess ROS. In addition to 
endogenous antioxidant defense systems, exogenous originating reducing compounds 
such as vitamin C, vitamin E, carotenoids and polyphenols are also required (Bouayed 
& Bohn, 2010).  
Classically ROS were considered deleterious agents, contributing to a vast 
range of pathologies, however, more recently their protective effects are being 
appreciated. In the past two decades, much focus has been placed on the concept that 
oxidants can function as part of signal transduction pathways (Sundaresan et al, 
1995). Various ROS have different physical and chemical properties that allow them 
to modify distinct target molecules. The reduction-oxidation (redox)-dependent 
signalling system is highly conserved and based on the oxidation and reduction of 
cysteine residues. Experimental evidence suggests that ROS generation causes 
reversible post-translational modification, not only of cysteine residues, but also of 
selenocysteine, methionine and histidine residues (Woolley et al, 2013). Although the 
mechanisms underlying ROS signalling are not fully understood, increasing numbers 
of ROS related observations coupled with advancements in methodologies for 
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analysing ROS are contributing to increased knowledge of redox signalling and 
consequent cascades. 
 
Source of ROS 
ROS are generated in numerous cellular compartments and by multiple 
enzymes within the cell (Finkel, 2011). It is estimated that approximately 90% of 
ROS can be traced back to the mitochondrion. Aerobic respiration results in the 
generation of ROS as a byproduct of the electron transport chain. Mitochondria 
generate ATP ultilising oxygen. During this process the flow of electrons down the 
respiratory chain gather at complex IV. In this scenario, O2
•− 
is formed when a single 
electron prematurely reduces O2. The major sites of superoxide production are 
thought to be in complex I and complex III of the electron transport chain. The result 
is release of ROS from mitochondria resulting in an intercellular environment of 
oxidative stress. Mitochondrial ROS have been classically considered as toxic, but 
their importance in intracellular signalling pathways is now acknowledged. It has 
become apparent that many cellular organelles and enzymes produce ROS not only as 
a byproduct, like the mitochondria but also as a primary function. In the last decade 
much research has focused on the phagocyte NAPDH oxidases (Nox) generating ROS 
as its preeminent role. These enzymes produce large amounts of ROS to execute their 
role in host defense. The Nox family consists of seven isoforms, Nox1-5 and the Dual 
oxidase (Duox) 1 and 2. The major source of ROS generation is a flavin- and haem- 
containing protein complex that removes electrons from cytosolic NADPH that are 
used to reduce molecular O2 and intentionally produce superoxide. Extracellular 
superoxide can re-enter the cell or become converted to hydrogen peroxide. Nox2 is 
the catalytic subunit of this complex, however, it does not stimulate superoxide on its 
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own. To do so it recruits a number of cytosolic factors including, p40phox, p47phox, 
p67phox and Rac1 GTPase as well as membrane bound p22phox (Woolley et al, 
2013). Studies on the physiological functions of Nox-dependent ROS generation are 
ongoing. 
While mitochondria and Noxs are the best-characterised sources of ROS, a 
host of other enzymes can produce these reactive molecules.  Peroxisomes, 
cytochrome P-450 enzymes, lipoxygenases, cyclooxygenases, xanthine oxidase and 
nitric oxide synthase are all capable of producing ROS. Just like the mitochondria and 
Noxs these enzymes can be grouped by those who generate ROS as a side effect and 
those who produce it as a primary function. ROS are generated as a byproduct of 
biological reactions involving peroxisomes (Schrader & Fahimi, 2004) and 
cytochrome P-450 (Gottlieb, 2003) while the lipoxygenase and cyclooxygenase 
families of enzymes produce ROS required for fatty acid metabolism and the 
biosynthesis of hormones and inflammatory mediators. 
 
ROS as signalling molecules 
Continuous creation and removal of ROS in a system is not only capable of 
causing damage, but also of conveying important information. Redox-signalling is 
achieved when the oxidants produced modulate a signal transduction pathway. These 
ROS must then trigger the oxidation-induced modification of specific target 
molecules. Bartosz summarised the requirements for a signalling molecule as follows: 
(i) regulating its concentration with regard to synthesis and removal, (ii) existence of 
specific receptors and (iii) reversibility of the signalling effect (Bartosz, 2009). Some 
ROS are superior signalling molecules to others. H2O2 is an excellent signalling 
molecule, as it is highly ubiquitous, can diffuse easily and is relatively stable allowing 
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it time to encounter specific targets. For these reasons, H2O2 is considered the 
prevailing intracellular redox-signalling molecule. In comparison, O2
•− 
becomes 
rapidly dismuted, lacks diffusibilty and its targets are limited to those within the 
immediate vicinity of its source.  Hydroxyl is an inadequate signalling molecule due 
to its high oxidation rate constant, which leads to highly non-specific oxidation. 
Peroxyl and alkoxyl possess aggressive reactivity and lack enzymatic-removal 
resulting in the outcome of their reactions being mainly irreversible oxidation events, 
ultimately leading to damage. Singlet oxygen rarely occurs intracellularly and so it is 
doubtful that it contributes to signal transduction. In contrast, HOCl has been 
suggested to function as a signalling mediator in immune cells (Corcoran & Cotter, 
2013). 
The precise mechanisms of ROS signalling are poorly understood. However, 
the concept that Cys residues can function as redox-dependent switches is thought to 
be the mechanism that underlies most ROS-dependent signalling (Woolley et al, 
2013). The main targets of H2O2 are a thiol group of protein cysteine residues (Figure 
3). Hydrogen peroxide oxidises cysteines to disulfides. The disulfide bonds can be 
reduced by glutaredoxins (Grxs), thioredoxins (Trxs) or glutathione (GSH). Therefore 
this modification is reversible. S-Glutathionylation formation of a mixed protein–
glutathione disulfide, known as S-Glutathionylation is thought to prevent further, 
irreversible oxidation of cysteine sulfur. Glutathionylation and deglutathionylation are 
catalysed by glutaredoxins. Additional oxidation of a thiol group leads to a sulfinic 
acids −SO2H or sulfonic acids −SO3H. Thiol groups are reactive primarily in their 
deprotonated form. The pKa of most cysteine thiols in proteins is approximately 8.5 
so these groups are mainly protonated. It is for this reason that Cys residues of low 
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pKa, being ionised at physiological pH, may be selectively oxidised, even in the 
presence of an excess of other Cys residues (Bartosz, 2009). 
 
 
 
 
Figure 1.3. Redox signalling pathway. A. Oxidative modification of cysteine 
residues by H2O2. B. ROS modulate receptor tyrosine kinase (RTK) signalling by 
regulating the redox state of protein tyrosine phosphatases (PTPs). When a peptide 
ligand such as PDGF binds to its receptor RTK the signal can involve activation of 
PI3K and other downstream target proteins of this kinase driven pathway, which 
result in activation of membrane Nox and generation of ROS. This ROS, acts on a 
redox-sensitive cysteine residue in the active site of PTPs and transform the -SH 
group into the oxidised S–S group, thus reversibly inactivating PTPs. Oxidation of 
cysteine residues leading to PTP inhibition results in a stronger signalling flux 
through the kinase arm of the pathway. 
 
A 
B 
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ROS in cancer 
Cancer initiation and progression have been linked to oxidative stress by 
increasing DNA mutations or inducing DNA damage, genome instability, and cell 
proliferation (Visconti & Grieco, 2009). One of the key characteristics of cancer cells 
compared to the normal cells is a persistent pro-oxidative state that can lead to 
intrinsic oxidative stress (Toyokuni et al, 1995). The Warburg effect refers to cancer 
cells having higher rates of glycolysis. Glucose normally produces ATP and lactate 
but can be redirected to the pentose phosphate pathway (PPP), yielding NADPH, 
which maintains GSH in its reduced state. Whether glucose produces ATP and lactate 
or generates NAPDH is largely determined by pyruvate kinase.  Increased levels of 
ROS target a unique Cys residue in pyruvate kinase M2 (PKM2), an isoform of 
pyruvate kinase expressed in tumour cells. The oxidized PKM2 diverts glucose 
towards the PPP leading to redox buffering by GSH (Anastasiou et al, 2011). The 
increased oxidative stress in cancer cells results not only from their increased 
metabolism but also inactivation of antioxidant mechanisms. Cancer cells have 
evolved mechanisms to protect themselves from intrinsic oxidative stress such as 
rearranging antioxidant functions and upregulating pro-survival molecules (Farber & 
Rubin, 1991).  
ROS may also contribute to the initiation of cancer through accelerating pro-
tumorigenic signalling pathways. ROS can oxidise disulfide bonds of cysteine 
residues, changing the activity of certain proteins, most notably the tyrosine 
phosphatases superfamily (Tonks, 2006). For example the inhibition of PTEN by 
ROS hyperactivates the PI3K/AKT signalling pathway, which is potentially the most 
frequently activated signalling pathway in cancer cells (Hay, 2005).  
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In contrast to its antitumorigenic actions, oxidative stress has also been linked 
to senescence and apoptosis, two major mechanisms that can act as barriers to tumour 
development (Visconti & Grieco, 2009). For example, alterations in ROS levels can 
activate p53, resulting in the induction of senescence (Vigneron & Vousden, 2010). 
This means that the high levels of ROS that cancer cells exhibit may be their Achilles’ 
heel as it makes them more susceptible to cell death. The precise connection between 
oxidative stress and cancer has yet to be elucidated.  
Treatment of acute myeloid leukaemia 
Treating AML is challenging. Standard therapy for AML patients consists of 
an induction therapy followed by consolidation therapy. Complete response rates can 
be as high as 80% in patients undergoing initial induction cytotoxic chemotherapy. 
However, the majority of AML patients will ultimately be diagnosed with relapsed or 
refractory disease (Lowenberg et al, 1999). These patients have a poor prognosis. 
Several factors have been associated with more severe outcomes at relapse, including 
unfavorable cytogenetics at diagnosis, duration of first complete response (CR) less 
than 12 months, older age, and prior history of hematopoietic stem cell transplant 
(HSCT) (Breems et al, 2005). However, even patients without these factors do not 
always achieve a second remission. 
 Clinical relapse of AML may be from three underlying sources: Firstly, a 
chemo-sensitive disease that was only partially treated and returns, perhaps even with 
additional mutations. Secondly, a sub-clone, derived from the same founder clone as 
the predominant clone. This clone may have been initially present at low frequency 
but given a clonal advantage during treatment due to decreased chemotherapy 
sensitivity. Thirdly, de novo generation of AML may occur due to toxicity from 
treatment although this mechanism is less common (Ramos et al, 2015).  
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Conventional AML chemotherapy 
The most commonly used induction regimens involve a combination of 
cytarabine (Ara-C) and either daunorubicin or idarubicin. Cytarabine is a 
deoxycytidine analog that is actively metabolised to arabinofuranosylcytidine 
triphosphate (ara-CTP) (Karanes et al, 1999). In general, patients with a good 
performance status who have not yet received high dose Ara-C (HIDAC) can receive 
this treatment regimen in the salvage setting. Even patients who suffer a late relapse 
can sometimes achieve a second CR by retreatment with the same initial induction 
regimen (O’Donnell et al, 2013). However, HIDAC monotherapy is far from an 
acceptable standard of care for relapsed AML.  
 
Novel AML chemotherapy 
As can be seen in Table 1.2, a number of chemotherapeutic agents are given in 
combination with Ara-C. As mentioned previously Ara-C is frequently administered 
with daunorubicin. Liposomal daunorubicin is now used as it is thought to have 
decreased toxicity compared to free daunorubicin (Verdonck et al, 1998). In the 
FLAG and ClAG regimens Fludarabine and Cladribine are employed. They act by 
inhibiting ribonucleotide reductase (RNR), which augments the rate of synthesis of 
ara-CTP in circulating AML blasts (Gandhi et al, 1993). Clofarabine shares this 
mechanism and also inhibits DNA synthesis (Scappini et al, 2012). In another 
regimen, combinations of mitoxantrone, etoposide and cytarabine have been 
evaluated in relapsed AML with multiple variations in the dose and schedule (Price et 
al, 2011). An ongoing phase II study is evaluating the effect of pre-treatment with 
decitabine, a hypomethylating agent, prior to this treatment (NCT01729845). More 
recently flavopiridolcan, which acts as a cyclin-dependent kinase inhibitor has been 
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used, although it appears to be too toxic for older patients (Karp et al, 2007). 
Vosaroxin, on the other hand, a quinolone derivative that intercalates DNA and 
inhibits topoisomerase II, is well tolerated by older patients (Hotinski et al, 2015). 
The two most recent agents to be added to the list are homoharringtonine and CPX 
351. Homoharringtonine is an alkaloid that when combined with cytarabine and the 
anthracycline aclarubicin, was shown to induce a higher CR rate than these agents 
alone. However, it is associated with infections (Yu et al, 2013). CPX 351 is not 
actually a drug but rather a bilamellar liposome that encapsulates cytarabine and 
daunorubicin in an optimally synergistic fixed molar ratio of 5:1 (Feldman et al, 
2011). There may be a benefit with CPX 351 for subjects with poor-risk disease 
(Cortes et al, 2015).  
 
Targeted AML chemotherapy 
The current rationale for developing new AML chemotherapeutics is targeting 
the deregulated pathways that drive blast proliferation. There are now a number of 
agents that target the various pathways that accelerate the disease. For example, 
deregulated metabolism can be manipulated. In 30% of de novo AML, mutations 
affecting two isoforms of the isocitrate dehydrogenase (IDH) enzyme, IDH1 and 
IDH2 can be found. AG-221 is a selective inhibitor of the mutated IDH2 and AG-120 
is an ADH1 inhibitor, which are currently in a phase I clinical study (Marcucci et al, 
2010). Kinase inhibition is a popular strategy due to the contribution of FLT-ITD. 
Quizartinib (AC220), a FLT3-ITD inhibitor has been shown in a phase I trial to be 
safe and efficacious in patients (Cortes et al, 2013). Another agent that was well 
tolerated in a phase I trial is Ruxolitinib (Pemmaraju et al, 2015). Other inhibitors of 
implicated pathways that are being investigated are rapamycin, vorinostat and 
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Table 1.2 Chemotherpy regimens utilised in patients with relapsed/refractory     
AML (Adapted from Ramos et al, 2015) 
 
Regimen Agents CR 30 Day 
Mortality 
HIDAC Cytarabine 3 g/m
2
 days 1-6 32-47% 12-15% 
FLAG FLAG-IDA Fludarabine 30 mg/m
2 
days 1-5 
Cytarabine 2 mg/m
2 
days 1-5 or 
+ Idarubicin 8 mg/m
2 
days 1-3 
48-55% 10-11% 
CLAG CLAG-M Cladribine 30 mg/m
2 
days 1-5 
Cytarabine 2 mg/m
2 
days 1-5 or 
+ Mitoxantrone 10 mg/m
2 
days 1-3 
38-50% 
 
50-58% 
0-17% 
 
0-7% 
MEC Mitoxantrone 6 mg/m
2 
days 1-6 
Etoposide 80 mg/m
2 
days 1-6 
Cytarabine 1 mg/m
2 
days 1-6 or 
Mitoxantrone 8 mg/m
2 
days 1-5 
Etoposide 100 mg/m
2 
days 1-5 
Cytarabine 1 mg/m
2 
days 1-5 
59-66% 
 
 
18-24% 
3-6% 
 
 
7-11% 
MEC/Decitabine Decitabine 20 mg/m
2 
days 1-10 
Mitoxantrone 6 mg/m
2 
days 16-20 
Etoposide 100 mg/m
2 
days 16-20 
Cytarabine 1 mg/m
2 
days 16-20 
30% 20% 
EMA-86 Mitoxantrone 12 mg/m
2 
days 1-3 
Cytarabine 500 mg/m
2 
days 1-3 & 8-10 
Etoposide 200 mg/m
2 
days 8-10 
60% 11% 
MAV Mitoxantrone 10 mg/m
2 
days 4-8 
Cytarabine 100 mg/m
2 
days 1-8 
Etoposide 100-200 mg/m
2 
days 4-8 
58% 11% 
FLAD Fludarabine 30 mg/m
2 
days 1-3 
Cytarabine 2 g/m
2 
days 1-3  
Liposomal daunorubicin 100 mg/m
2 
days 1-3 
53% 7.5% 
FLAM Flavopiridol 50 mg/m
2 
days 1-3 
Cytarabine 2 g/m
2 
starting day 6 
Mitoxantrone 40 mg/m
2 
day 9 
28-43% 5-28% 
Clofarabine 
Cytarabine 
Clofarabine 40 mg/m
2 
days 2-6 
Cytarabine 1 g/m
2 
days 1-5 
28-51% 6-13% 
HAA Homoharringtonine 4 mg/m
2 
days 1-3 
Cytarabine 150 mg/m
2 
days 1-7 
Aclarubicin 12 mg/m
2 
days 1-7 
76-80% 0% 
CPX 351 CPX 351 100 units/m
2 
days 1, 3 and 5 23-37% 7-13% 
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bortezomib. Rapamycin is an inhibitor of a serine/threonine kinase involved in the 
regulation of cell growth and proliferation by translational control of key proteins 
(Recher et al, 2005). Vorinostat is a histone deacetylase inhibitor (Schaefer et al, 
2009), while bortezomib a proteasome inhibitor (Chen et al, 2011).  
Interestingly, an alternative approach to inhibiting these pathways is 
combining statins with conventional chemotherapy. AML blasts frequently 
overexpress the genes for the low-density lipoprotein (LDL) receptor. Blocking 3-
hydroxy-3-methylglutaryl coenzyme reductase (HMG-CoAR) inhibits cholesterol 
uptake and synthesis, therefore sensitising cells to cytotoxic therapy (Kornblau et al, 
2007). A phase II study evaluating pravastatin, intermediate-dose cytarabine, and 
idarubicin is underway. 
 
AML immunotherapy 
Immunotherapeutic interventions are aimed at directing an immune response 
against tumour cells. CD123 and CD33 are the two main targets in AML 
immunotherapy. CSL362 is a humanised second-generation anti-CD123 antibody. It 
was found to be safe and well tolerated as maintenance therapy in a phase I study and 
a phase II study is planned (Busfield et al, 2014). GN-CD33 is an anti-CD33 
antibody, which has showed favorable results in a preclinical study (Borthakur et al, 
2013). However, anti-CD33 antibodies were previously found to be unsuccessful in 
the later stages clinical trials (Feldman et al, 2005). 
 Adoptive cell transfer is another immunotherapeutic approach. Chimeric 
antigen receptor-transduced T cells (CART) are synthetic transmembrane constructs 
that combine the specificity of antibody target recognition with the potent effector 
mechanisms of T-cell immunity. CARTs have been designed to target CD33 
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(CART33) and CD123 (CART123) in AML (Wang et al, 2015). A number of studies 
have looked at vaccination with different leukaemia-associated antigens. These 
studies have generally demonstrated safety but no clinical efficacy as a monotherapy. 
However, a recent phase I/II study showed that they have promise in an adjuvant 
setting (NCT01266083). 
 Allogenic Hematopoietic Stem Cell Transplant (AlloHSCT) is a topical AML 
therapy. AlloHSCT offers patients the best chance of achieving remission, provided 
they have a good performance status and an adequate donor. Unfortunately the less 
than ideal performance status of most elderly patients limits their access to this 
therapy. Stem cell sources include a matched-related donor, a match-unrelated donor, 
double cord blood units or a haploidentical family donor. AML patients who relapse 
after transplantation have bleak survival prospects (Ramos et al, 2015).  
 
Summary of AML therapy 
Most patients who are diagnosed with AML will die of AML. The 
fundamental problem in the treatment of AML is that available therapies are simply 
not effective enough. AML has historically been approached as a homogeneous 
diagnostic entity. This is clearly not the case; in reality the acute myeloid leukaemias 
are a heterogeneous group of diseases with distinct molecular and phenotypic 
characteristics. Hopefully in the future, advances in genome sequencing technology 
will allow for timely and economically feasible personalised therapy. However, at the 
moment this is not feasible. It seems that since there is obvious standard of care, that 
all patients with refractory or relapsed AML be offered a referral to an appropriate 
clinical trial where possible (Ramos et al, 2015). This lack of standard care also 
highlights the urgent need to develop better drugs to treat AML. 
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Ellipticine  
Ellipticine was first isolated from the leaves an Oschrosia Elliptica Labill tree 
by Goodwin et al. in 1959. Multiple synthetic routes to ellipticine have since been 
developed, which have been reviewed comprehensively Miller & McCarthy (2012). 
Ellipticine has been the focus of extensive pharmacological research due to the 
discovery of its anti-tumour effects.  
Ellipticine mechanisms of action 
The mechanisms of action of ellipticine are considered in three sections: 
interaction with DNA, kinase inhibition and other mechanisms. Initially, research on 
mechanisms of action focused on its interaction with DNA. These interactions are 
well established and include DNA intercalation (Lerman, 1961), topoisomerase II 
inhibition (Ross et al, 1978) bio-oxidation and adduct formation (Auclair & Paoletti, 
1981). This was followed by elucidation of its ability to inhibit kinases such as AKT 
(Jin et al, 2004), c-Kit (Vendome et al, 2005). More recently, it has been 
demonstrated that ellipticine is capable of interacting with p53 tumour suppressor 
protein (Peng et al, 2003), producing mitochondrial damage (Calabro et al, 2015) and 
inducing endoplasmic reticulum stress (Hagg et al, 2003). As such, it is clear that 
ellipticine exhibits a multimodal cytotoxic activity.  
 
Figure 1.4. Ellipticine 
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Intercalation 
Intercalation occurs when a planar aromatic or heteroaromatic ring is 
introduced between base pairs of DNA and alters its structure (Lerman, 1961). Once 
bound, the drug can inhibit enzymes involved in replication and transcription. Canals 
et al established an intercalation model with ellipticine parallel to the axis of the base 
pairs with the pyridine nitrogen facing the major grove (Canals et al, 2005). However, 
derivatives of ellipticine may intercalate differently or possibly not at all.   
  Topoisomerases are enzymes that regulate the topology of DNA. 
Identical loops of DNA with different numbers of twists are topoisomerases. 
Interconversion of these topoisomers requires breaking of DNA strands. 
Topoisomerase I produces single strand breaks in DNA, allowing the release of 
tension while topoisomerase II produces double strand breaks, allowing separate 
strands to untangle (Champoux, 2001). Both of these processes are essential for 
replication and transcription. Ross and Bradley first established the association 
between ellipticine DNA strand breaks with topoisomerase II inhibition (Ross & 
Bradley, 1981). Holden et al measured topoisomerase activity in normal and 
neoplastic tissues (Holden et al, 1990). In normal tissue, the highest levels were found 
in the spleen and thymus. In neoplastic tissue, the highest were found in breast cancer 
and lymphoma, tissues that are clinically most aggressive and proliferative. Therefore 
topoisomerase II may be a key target for cancer chemotherapy. 
 Auclair and Paoletti first showed that derivatives of ellipticine could undergo 
bio-activation to more active compounds. They found that 9-hydroxyellipticine was 
oxidised to the quinone imine, which is a strong electrophile, oxidising NADH to 
NAD+ (Auclair & Paoletti, 1981). Following on from this, Stiborova et al have 
extensively investigated the bio-oxidation and adduct formation pathways of 
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ellipticine. They investigated the potential of ellipticine to form DNA adducts after 
activation by cytochrome P450 (CYP). 13-Hydroxyellipticine and the ellipticine N-
oxide were identified as the metabolites responsible for the two adducts which are 
formed (Stiborova et al, 2007). 
Kinase inhibition 
c-Kit kinase is a type III receptor tyrosine kinase (RTK). c-Kit plays a role in 
cell survival, differentiation, maturation and function. It is particularly important for 
the growth and development of hematopoetic stem cells (Edling & Hallberg, 2007). 
Mutations in the gene encoding for c-Kit kinase are associated with some highly 
malignant cancers. Therefore c-Kit kinases are a promising target in anticancer 
chemotherapy. Longley et al classified activating mutations into two groups, 
enzymatic pocket mutations and regulatory mutations. Wild-type c-Kit inhibitors are 
effective at inhibiting both wild-type and regulatory type mutations (Longley et al, 
2001). Imatinib is a good example of this principle. However, they are not successful 
at inhibiting c-Kit kinase with enzymatic pocket mutations. This is unfortunate as the 
most common mutation is a D816V point mutation, an enzymatic pocket type 
mutation (Corless et al, 2006). Treatment is extremely limited and fails to produce 
remission in most patients. However, in 2005, Vendome et al showed that several 
ellipticine derivatives significantly inhibited both wild type and D816V mutated c-Kit 
kinase. 
AKT is known to play a role is survival as it phosphorylates Bad, glycogen 
synthase kinase-3 (GSK-3), forkhead transcription facfor (FKHR) and caspase 9. 9-
Methoxy-N-methylellipticinium acetate has been shown to inhibit AKT kinase 
activity. Interestingly this inhibition is only seen in cell lines with over-activation of 
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AKT but had a minimal effect on normal cells (Jin et al, 2004). 
Other 
Interaction with p53 
p53 is a tumour suppressor gene better known as the ‘guardian of the genome’ 
due to its role in conserving stability. p53 has a dual role as it can have different 
effects under conditions of low-stress compared to sustained stress. In general under 
conditions of low-stress, p53 promotes repair of genotoxic damage and cell survival. 
Contrastingly, in a situation of sustained stress p53 activates cell death (Janus et al, 
1999). p53 is encoded by the TP53 gene. This gene is mutated or deleted in 
approximately 55% of cancers (Ahrendt et al, 2003).  
 Peng et al showed that ellipticine and several derivatives can activate the 
transcription function of p53. In wild type p53 cells, ellipticine derivatives induced 
cell cycle arrest while in mutant p53 cells, treatment with ellipticine resulted in 
apoptosis. In mutant p53-transfected H1299 cells, treatment with ellipticine induced a 
shift of mutant p53 conformations towards that of wild type, restoring function (Peng 
et al, 2003). Kuo showed that ellipticine activity in MCF-7 cells, a breast cancer cell 
line, induced p53, Fas/Fas ligand death receptor activation and the mitochondrial 
proapoptotic pathway (Kuo et al, 2003). Recent studies in this area have focused on 
the combination of ellipticine with existing anti-cancer agents. For example, in 
chemo-resistant mutant p53 Ramos cells, ellipticine sensitised cells towards 
doxorubicine-induced apoptosis (Wang et al, 2011a). 
Mitochondrial damage 
Schwaller et al examined ellipticine-induced uncoupling of mitochondrial 
oxidative phosphorylation and found that it has a potent effect on the mitochondria. 
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Tian et al identified an ellipticine derivative, 9-(N,N-dimethyl ethanamine)-
oxyellipticine as a lead compound with respect to affecting the mitochondria (Tian et 
al, 2008). This compound was found to accumulate in the mitochondria and initiate 
loss of mitochondrial membrane potential, release of cytochrome C and formation of 
large vacuoles (Schwaller et al, 1995). 
Induction of endoplasmic reticulum (ER) stress 
Research on this mechanism is less extensive than the others mentioned. Hagg 
et al are the main contributors as they showed that 6-propanamine ellipticine induced 
endoplasmic reticulum stress, followed by release of cytochrome C from 
mitochondria and caspase cleavage of CK18. However, the extent of this mechanism 
to the overall cytotoxicity of the compound is unclear (Hagg et al, 2003). 
Induction of reactive oxygen species (ROS) 
The most recent mechanism of action of ellipticine that is being investigated is 
the generation of ROS. Only four years ago, Kim et al showed that the production of 
intracellular reactive oxygen species (ROS) was increased and sustained at high levels 
during ellipticine treatment. This ROS accumulation was found to activate 
extracellular-signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) (Kim 
et al, 2011). As with the induction of ER stress, the contribution of this mechanism 
has yet to be evaluated but certainly warrants further investigation.  
Design of ellipticine derivatives 
Clearly ellipticine has potent anticancer activity, however, properties such as 
low solubility and bioavailability have impeded their use in a clinical setting. To this 
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end, a range of ellipticine derivatives have been synthesised and evaluated for 
potential improvement in cytotoxicity.  
 
 
Figure 1.5. Main targets for ellipticine derivatisation 
 
 In 1976, Le Pecq et al carried out a study on the anti-tumour activity of 9-
hydroxyellipticine in a mouse model of leukaemia. Unfortunately this derivative did 
not have the ability to penetrate tumours efficiently. Celiptium and Datelliptium were 
shown to have superior cytotoxicity to 9-hydroxyellipticine but did not progress 
beyond phase II clinical trials. In 1979, Bisagni et al prepared 1-aminoellipticines, 
however, no further significant improvements were made.  
 NCI screening of 9-methoxy analogues showed selectivity towards CNS 
cancer cell lines. After investigation on the selectivity of 9-substituted N-
methylellipticium salts by Acton et al and Anderson et al in 1994, Vistica et al 
concluded that this selectivity was due to its preferential transport.  Jurayj et al 
 
14 
 
3.3 Ellipticine derivatives as intercalators and topoisomerase II inhibitors 
In order to increase potency, bioavailabilty and solubility relative to the parent compound 
various derivatives of ellipticine have been synthesised. The main sites of derivatisation are 
shown in Figure 10. 
 
 
 
 
 
 
 
 
FIGURE 10 Main targets of ellipticine derivatisation 
All of the derivatives shown in Table 1 have a binding constant in the region of 10
6
M
-1 
indicating that a high affinity for DNA is required for cytotoxicity. However a nonlinear 
regression analysis has indicated that the apparent affinity cannot be correlated significantly 
with cytotoxicity in culture [6]. For example, compounds such as 9-aminoellipticine 12 and 
6N-alkylellipticinium derivatives possess Kapp values of 2.0 x 10
6
M
-1 
or more
 
yet exhibit low 
cytotoxicity indicating additional parameters are necessary to predict the cytotoxicity of 
ellipticines. 
Fosse et al. examined the structure activity relationship for ellipticine derivatives and 
topoisomerase II inhibition [54].  From their results (included in Table 1 above) they divided 
the ellipticine derivatives into two main groups, 9-hydroxylated derivatives which had a 
relative frequency of DNA cleavage of 3.3-8.2 and derivatives which possessed neither a 
hydroxyl or an amino group at the 9 position. This latter group stimulated cleavage by a 
factor of 0.8 – 1.9. Therefore hydroxylation at position 9 on average raised the relative 
frequency of DNA cleavage from 1.6 to 4.4. Quaternization at the pyridine nitrogen with 
either a methyl group or a diethylaminoethyl chain did not significantly affect the cleavage 
potency for both the hydroxylated and non-hydroxylated compounds. Substitutions at 
position 1 did not significantly alter cleavage frequency. For 9-hydroxy-2-
methylellipticinium 3 the substitution of an ethyl group at position 5 instead of a methyl 
group significantly increases the cleavage potency. This derivative 17 was also active over a 
much wider concentration range th n th other derivatives. They found the introduction of the 
ethyl group decreased the binding constant and the unwinding angle produced by drug 
binding compared to derivatives such as 9-hydroxy-2-methylellipticium 3, 1,2-dimethyl-9-
hydroxyellipticinium 14 and  2,6-dimethyl-9-hydroxyellipticinium 8. They proposed that 
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proposed that while this was the case in vitro, the ability of a charged ion to cross the 
blood-brain barrier (BBB) in vivo was relatively low. Therefore, neutral 2-alkyl-1,2-
dihydroellipticines were prepared as they could theoretically cross the BBB. 
Unfortunately, some of these compounds were unstable in solution and converted 
back to ellipticines. Those that were stable showed little growth inhibition in the NCI 
60 cell line screen (Jurayj et al, 1994).  
 In 1988 Honda et al prepared N-glycosides of ellipticine to improve water 
solubilty and selectivity towards tumour cells. Two compounds L-arabinopyranoside 
and D-xylofuranoside were found to be curative in a leukaemia mouse model. 
However, no further literature is available, suggesting that these compounds failed at 
a preclinical phase. 
Isoellipticines 
Isoellipticine is a non-natural isomer of ellipticine, which differs at the 
position of nitrogen in the pyridine ring. Isoellipticine, which was first synthesised in 
1967 (Fujiwara et al, 1967) possesses similar anticancer properties to ellipticine but 
has not been extensively investigated. Interestingly low correlation between results of 
the topoisomerase II decatenation assay and NCI screen throughout the panel suggest 
that topoisomerase II is not the most important biological target with respect to anti-
cancer activity in this new class of compounds (Miller et al, 2012).  
Recent advances in ellipticine research 
Recent research in this area has focused on the transport of ellipticine. At the 
time of writing, the most recent paper on ellipticine showed that native human serum 
albumin (HSA) is responsible for transport of neutral species of ellipticine whereas 
immunoglobulin G (IgG) carries cationic ellipticine in its native form (Thakur et al, 
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2015). Additional research has concentrated on delivery of ellipticine. It has been 
found that supramolecular polymer conjugate is a good candidate for the delivery of 
ellipticine-based drugs (Studenovsky et al, 2015). Furthermore, Sedlacek et al. have 
described an optimised triple-targeted polymer delivery system for ellipticine, which 
contains radioisotope iodine-125 with high specific radioactivity (Sedlacek et al, 
2015). 
Objectives 
 It is clear that AML is a complex, heterogeneous disease with high relapse 
rates. These factors contribute to the difficulty with treating this disease (Lowenberg 
et al, 1999). As highlighted in this report current AML therapeutics are simply not 
efficient enough (Ramos et al, 2015). In light of this, isoellipticines represent a novel 
compound class with chemotherapeutic potential. The aims of this study were to 
determine the effect of these ellipticine derivatives on leukaemia cell lines and to 
probe their mechanism of action. More specifically, I wanted to investigate the 
compounds effects on ROS production and the main pathways driving 
leukaemogenesis. Furthermore, I sought to determine if isoellipticines bear potential 
clinical application.
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Chemicals and Reagents 
The ROS probes dihydroethidium (DHE) (D-1168), MitoSOX (Red 
Mitochondrial Superoxide Indicator (M36008) and MitoTracker deep red dye 
(M22436) were purchased from Molecular Probes (Life Technologies, Dublin, 
Ireland).           
 The reagents used to modulate ROS activity; ebselen (SML0419), diclofenac 
(D6899), diphenyleneiodonium chloride (DPI) (D2926), rotenone (R8875), 
lonidamine (L4900) and myxothiazol (T5580) were purchased from Sigma-Aldrich 
(Dublin, Ireland).          
 The compounds that were used for the combination study: cytosine β-D-
arabinofuranoside (Ara-C) (c1768), daunorubicin (30450), SP600125 (s5567) and 
butylated hydroxyanisole (W218308) were also purchased from Sigma-Aldrich with 
the exception of VAS-2870 (3-benzyl-7-(2-benzoxazolyl)thio-1,2,3- triazolo[4,5-
d]pyrimidine) (BML-EI395-0010), which was purchased from Enzo Life Sciences 
(Lausen, Switzerland). 
Antibodies 
Primary antibodies used for western blotting were γH2AX (#9719), p53 
(#9272), p21 Waf1/Cip1 (#2947), Cyclin B (#4135), Phospho-cdc2 (#9111), AKT 
(#9272), Phospho-AKT (#9271), JNK (#9252), Cyclin D2 (#D52F9), Cyclin D3 
(#2936), phospho-JNK (#9255), Beclin-1 (#3738), PI3K (#2947), pPI3K (#4228), p62 
(#5114), pERK (#9101), ERK (#9202), pp38 (#9211), p38 (#9212) and Caspase-3 
(#9662) all from Cell Signalling Technology, Boston, MA, USA. c-Myc (BD554205) 
was purchased from BD Biosciences Europe, Oxford, UK, while the Oxphos cocktail 
antibody (ab1104131) was purchased from Abcam, Cambridge, UK. All secondary 
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antibodies for western blotting were from the LI-COR Odyssey infrared imaging 
system (LI-COR Biosciences UK Ltd, Cambridge, UK). 
 
Isoellipticine synthesis 
Isoellipticine was synthesised from indole in five steps using a synthesis 
developed by Gribble et al. (Gribble et al, 1992). The isoellipticine derivatives used 
in this study were synthesised from isoellipticine in two steps via an aldehyde 
intermediate, using synthetic approaches previously detailed (Miller et al, 2012). The 
compounds were prepared by Elaine O’Sullivan in Dr. Florence McCarthy’s 
Laboratory, Chemistry Department, University College Cork. The compounds were 
subsequently dissolved in either Dimethyl Sulfoxide (DMSO) or polyethylene glycol 
(PEG) 400-water mixture (30% PEG 400, volume/volume). 
 
Spectral characterisation 
Luminescence spectra were recorded on a LS50B luminescence spectrometer 
(PerkinElmer). Fluorescence of MV4-11 cells incubated with 5 μM of each derivative 
for 24 hours was measured using a FACSCalibur flow cytometer (BD Biosciences 
Europe, Oxford, UK).  
 
Culture of leukaemia cell lines 
The human leukaemic cell lines MV4-11, HL60, Jurkat, K562, U937 and 
Molt-3 were purchased from DSMZ (Braunschweig, Germany). 32D, a murine 
immortalised myeloblast-like cell line, stably transfected with FLT3-ITD, was a kind 
gift from Prof. Hubert Serve from Goethe University Frankfurt and Prof. Frank D. 
Bohmer from the Universitatsklinkium Jena in Germany. Cells were maintained in 
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RPMI 1640 medium supplemented with 10% foetal calf serum, 2 mM L-glutamine 
and 1% penicillin/streptomycin (all from Sigma-Aldrich, Dublin, Ireland) in a 
humidified incubator at 37 °C with 5% CO2. For the 32D ITD cell line, 10% WEHI-
conditioned medium was added as a source of interleukin-3 (IL-3). The WEHI 
conditioned medium was harvested from a 48 hour culture of WEHI, a macrophage-
like, derived from a BALB/c mouse treated for tumour induction cell line, which 
produce and secrete IL-3. Cells were maintained between 0.2-1.0 x 10
6
 cells/ml and 
were sub-cultured every 2-3 days. 
Culture of primary leukaemia cells 
Human neutrophilic polymorphonuclear cells (PMNs) were isolated from 
venous blood of adults using standard dextran sedimentation and gradient separation 
on Histopaque 1077 (#10771, Sigma-Aldrich, Dublin, Ireland). Blood samples were 
obtained from 3 AML patients. Informed consent was obtained from
 
all of the 
patients. The clinical research ethics committee of the Cork teaching hospitals 
approved this study. Subsequent to isolation, PMNs were subjected to overnight 7-
hydroxyisoellipticine treatment, at the indicated concentrations. 
 
Cell cycle 
Cells were incubated with the indicated concentration of isoellipticine 
derivative for 24 hours, washed in phosphate-buffered saline (PBS) (pH 7.4) and 
fixed for 1 hour in ice-cold 70% ethanol. Fixed cells were incubated with RNaseA 
(0.02 mg·ml-1) (Boehringer, Ingelheim, Germany) for 40 minutes at 37°C. Nuclei 
were stained with propidium iodide (40 mg·ml-1) and analysed by flow cytometry 
using a FACSCalibur flow cytometer (BD Biosciences Europe, Oxford, UK). Cell 
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cycle distribution was analysed using this software. 
 
MTT assay 
The MTT assay was performed using the CellTiter 96 Non-Radioactive Cell 
Proliferation Assay (MTT) (Promega, Southampton, UK) according to the 
manufacturer's protocol. In brief, after 24 hours of incubation with the test 
compounds, 100 μL of medium, containing approximately 20,000 cells, was removed 
from each well. Then, 15 μL of the MTT solution was added and plates incubated for 
the optimised time of 1 hour at 37 °C. After incubation with MTT, the solubilisation 
solution was added for a further hour. Absorption of the produced formazan was 
measured at 570 nm using a microplate reader (Spectramax Plus).  
 
Western Blotting 
Cells were lysed with RIPA buffer [Tris–HCl (50mM; pH 7.4), 1% NP-40, 
0.25% sodium deoxycholate, NaCl (150mM), EGTA (1mM), sodium orthovanadate 
(1mM), sodium fluoride (1mM), cocktail protease inhibitors (Roche, Welwyn, 
Hertforshire, UK) and 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride 
(200mM)] for 20 minutes on ice followed by centrifugation at 14,000 g for 15 
minutes to remove cell debris. Equivalent amounts of protein, as determined by the 
Bio-Rad Protein Assay (Bio-Rad, Hemel Hempstead, UK) were resuspended in 
loading dye with Dithiothreitol (DTT; Sigma-Aldrich) and boiled at 95°C for 5 
minutes, with the exception of the lysates to be probed for the pFLT3 and FLT3 
antibodies, which were not boiled. This solution was then centrifuged at 16,000 g for 
1 minute and the total supernatant resolved using SDS–polyacrylamide gel 
electrophoresis, followed by transfer to nitrocellulose membrane (Schleicher and 
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Schuell, Dassel, Germany) and incubated overnight with the appropriate antibodies. 
Antibody reactive bands were detected using a LI-COR Odyssey infrared imaging 
system (LI-COR Biosciences UK Ltd, Cambridge, UK). 
 
Colony formation assay  
A total of 10,000 MV4-11 cells were resuspended in MethoCult H4034 
medium (Stemcell Technologies, Grenoble, France) and plated into a 35 mm-dish. 
After 14 days, colonies were counted.  
 
Analysis of cell number and cell viability 
Cells were incubated in 2 ml of RPMI 1640 medium in six-well plates at 37°C 
for 24 hours with the indicated concentration of isoellipticine derivative or 0.5% 
DMSO control. Numbers and viability of the cells were determined by counting with 
a haemocytometer after staining with trypan blue (#T8154, Sigma-Aldrich).  
 
ROS measurement 
Total intracellular superoxide anion levels were measured by incubating cells 
with 10 μM of DHE added to the medium for 15 minutes at 37 °C in the dark. Cells 
were then briefly washed with phosphate buffered saline (PBS) and immediately 
analysed by flow cytometry using FACSCalibur (BD Biosciences, Europe) and 
Cellquest Pro software (Beckton Dickinson). The fluorescent intensity of cells of 
10,000 events was recorded. The viability of the cells, based on their size and 
granularity, was estimated using FSC-H and SSC-H lasers. The geometric mean of 3 
technical replicates of fluorescence of viable cells was calculated. Mitochondrial ROS 
were measured using the MitoSOX probe. The cells were incubated with 5 μM of 
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freshly prepared MitoSOX for 15 minutes in the dark at 37 °C. The incubation was 
followed by PBS washing and analysis by flow cytometry as explained above.  
 
γH2AX immunofluorescence             
   Approximately 200,000 cells were washed for 5 minutes in PBS and 
cytopsun for 2 minutes at 500 g onto the slides. The slides were allowed to dry for 1 
hour. Following drying, cells were fixed for 1 hour in 3% PFA/PBS. The fixing step 
was followed by a 5 minutes PBS wash. The slides were incubated in 70% ethanol 
overnight at -20 °C. The next day, the cells were washed twice with PBS for 5 
minutes each time. The antigens were blocked for 15 minutes using 5% FBS/PBS and 
incubated with 50 μL of γH2AX primary antibody (1/100 in 5% FBS/PBS) and 
Hoechst solutions (1:1000 in 5% FBS/PBS) at room temperature for 1 hour in 
humidification chambers. Washing with PBS followed the primary antibody 
incubation. Cells were visualised on a Leica DM LB2 fluorescence microscope 
(Leica, Nussloch, Germany) using a TRITC filter. Images of the cells were acquired 
by Nikon Digital Sight DS-Fi1C camera (Nikon, Japan) using NIS-Elements software 
(version 3.0, Nikon, Japan).  
Microscopy                 
     Cells were cytospun, using a Shandon CytoSpin II Cytocentrifuge at 500 g 
for 2 minutes and allowed to dry for 1 hour at room temperature. They were then 
fixed in 70% ethanol for 1 hour before being stained using conventional haematoxylin 
or Giemsa-Wright staining. Cells were then viewed under a light microscope (Leica 
DM LB2).  
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Hematoxylin staining 
Following cytospinning of the MV4-11 cells and sectioning of the organs 
respectively on to slides, slides were stained for 7 minutes with haematoxylin 
(GH5232, Sigma-Aldrich), then washed gently in running tap water for 5 minutes. 
Slides were then immersed in 1% acid alcohol for 30 seconds and in blue stain for a 
further 30 seconds. Slides were again washed gently in running tap water for 5 
minutes. This was followed by staining in aqueous eosin (HT110332, Sigma-Aldrich) 
for 15 minutes and a subsequent final wash in running tap water for 5 minutes. Slides 
were dehydrated quickly through 50%, 75%, 90% and 100% ethanol and allowed to 
clear in HistoChoice (Sigma-Aldrich, H2779) for 5 minutes. Cover slips were 
mounted using DPX (100503-834, VWR) and left to dry in a fume hood overnight 
before imaging. 
Giemsa Wright staining 
Following cytospinning of the MV4-11 cells on to slides, slides were stained 
for 5 minutes with Giemsa Wright stain (GS500, Sigma-Aldrich). Slides were then 
thoroughly rinsed with running water and allowed to air dry before mounting. 
Live cell imaging 
MV4-11 cells were incubated overnight on the poly-D-lysine (#P4707, Sigma-
Aldrich) coated glass bottomed dishes (#P35G-1.5-14-C; MatTek Corporation, 
Ashland). The next day these cells were treated with 5 μM isoellipticine derivative for 
the indicated time. Confocal fluorescence live imaging studies were performed with a 
Zeiss LSM510 META confocal microscope fitted with a 6361.4 plan apochromat 
lens. Excitation of Mitotracker deep red at 543 nm was carried out with Ar laser and 
emission was collected between 560–615 nm. Excitation of 7-formyl-10-
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methylisoellipticine at 488 nm was carried out using Ar laser and emission was 
collected between 505–530 nm. The multi-tracking mode of scanning was applied for 
acquisition of the settings.  
 
Combination assay 
MV4-11 cells were treated simultaneously with 7-formyl-10-
methylisoellipticine and the other compound of interest for 24 hours. Viability was 
then measured using the trypan blue exclusion assay and the synergy was evaluated 
by the method of Chou and Talalay with CompuSyn freeware (ComboSyn Inc.) 
(Chou, 2010). 
 
Animals 
All animal experimental procedures were approved by the ethical committee 
at the University College Cork and performed in accordance with the European Union 
(Protection of Animals Used for Scientific Purposes) Regulations 2012 (S.I. No. 543 
of 2012) and Directive 2010/63/EU for animals used for scientific purposes. Animals 
were culled by cervical dislocation. 
 
In vivo toxicity of 7-formyl-10-methylisoellipticine  
The in vivo toxicity of 7-formyl-10-methylisoellipticine was assessed using 
female BALB/c mice (6–8 weeks, Harlan Laboratories, UK). 7-Formyl-10-
methylisoellipticine was first dissolved in DMSO followed by dilution with a 
polyethylene glycol (PEG) 400-water mixture (30% PEG 400, volume/volume), 
which achieved the resultant solution with less than 1% DMSO. Animals (5 
mice/group) were intraperitoneally (i.p.) injected with 7-formyl-10-
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methylisoellipticine at doses of 5, 10, 20, 25 and 50 mg per kg body weight in a 
0.2 ml injection volume at the indicated times. The mice were sacrificed on day 25.  
 
In vivo anti-tumour effect of 7-formyl-10-methylisoellipticine  
Female CB17 severe combined immunodeficient (SCID) mice (6 weeks, 
Harlan Laboratories, UK) were used for in vivo anti-tumour study. The tumour-
bearing model was established by subcutaneous injection of MV4-11 cells [1 x 10
7
 in 
50% BD Matrigel
TM
, BD Biosciences (#354234) into the right flank of mice] (Gozgit 
et al, 2011). When the average tumour volume reached approximately 200 mm
3
, 
animals (8 mice/group) were i.p. injected with 7-formyl-10-methylisoellipticine at a 
dose of 25 mg per kg body weight in a 0.2 ml injection volume. Tumour growth was 
recorded regularly, and tumour volume was calculated using the formula a
2
b(π/6), 
where a is the minor diameter of the tumour and b is the major diameter perpendicular 
to diameter a. The mass of each tumour was also recorded at the end-point of the 
experiment. 
 
Organ analyses  
Organs of interest were dissected and segments of each organ were fixed 
overnight at 4°C in 10% formalin. Organs were cyroprotected in 15% sucrose in 
1xPBS for 1 hour, 20% sucrose in 1xPBS for 1.5 hours and 30% sucrose in 1xPBS 
overnight, all at 4°C. Organ segments were submerged and frozen in cyrochrome 
(Thermo Scientific) and sectioned on a cryostat. 7 μm sections were collected and 
stored at -80°C. Sections were stained with haematoxylin & eosin, coverslipped and 
imaged using the protocol described previously. 
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Liver injury analysis 
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST), levels 
in blood serum were determined using commercial assay kits (Sigma-Aldrich, 
#MAK052 and #MAK055). Serum was collected at the time of culling. 
 
Statistical analysis 
For the in vitro data values are mean ± standard deviation (SD) and are 
representative of at least three individual experiments. Data were statistically analysed 
using Student t-test. Two-way ANOVA with repeated measures was used to test the 
significance of differences in measured tumour growth and body weight. In all 
cases, p < 0.05 was considered statistically significant. 
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Abstract                                                                                                                                                      
 A panel of novel ellipticine isomers were designed and synthesised with the 
aim of evaluating their anti-cancer effects on selected leukaemia cell lines. A 
preliminary NCI 60-cell screen demonstrated that these compounds displayed 
promising anti-tumour activity across a number of different cell types. We 
consequently examined the effect of these derivatives in detail on the Acute Myeloid 
Leukaemia (AML) cell line, MV4-11. Cell cycle analyses revealed that the 
compounds had a range of distinctive cell cycle effects. 7-Hydroxyisoellipticine 
showed the most promise with respect to cytostatic activity. We demonstrated that 
this compound inhibited proliferation of leukaemia cells by preventing cells from 
progressing from G2 phase into mitosis over a period of 24 hours at a concentration of 
5 μM. Our research suggests that this is mediated by an induction of reactive oxygen 
species (ROS), which in turn activates the DNA damage response pathway. As a 
result of the activation of p53, cyclin B1 is inhibited. The induction of this pathway 
leads to apoptosis which is seen at 48 hours using the same dose of 7-
hydroxyisoellipticine. This study provides for the first time detailed cellular 
information on the potential use of isoellipticines as chemotherapeutic agents. 
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Introduction 
Ellipticine (5,11-dimethyl-6H-pyrido[4,3-b]carbazole) was first isolated from 
the leaf of Ochrosia elliptica Labill by Goodwin et al. in 1959 (Goodwin et al, 1959) 
and was found to display potent anticancer activity (Dalton et al, 1967). Despite this, 
its use in a clinical setting has been limited due to low solubility and bioavailability 
(Sbai et al, 1996). To overcome these limitations, a range of novel ellipticine 
derivatives have been synthesised and evaluated for potential improvement in 
cytotoxicity. The panel of isoellipticines vary at the 2-, 7- and 10-positions marked in 
the schematic drawing (Figure 3.1 A). Isoellipticine differs to ellipticine by the 
position of nitrogen on the pyridine ring. 
 
 
 
The NCI 60-cell line screen measured the preliminary cytotoxic activity of 
these compounds (Miller et al, 2012). This service is provided by the Developmental 
Therapeutics Program (DTP) at the US National Cancer Institute and involves 
submission of novel compounds for evaluation of activity against 60 different human 
tumour cell lines, representing leukaemia, melanoma and cancers of the lung, colon, 
brain, ovary, breast, prostate, and kidney.  
(a) 
(b) 
Figure 3.1. Structure and synthesis of isoellipticine. (a) Structure of isoellipticine with 
positions of modification marked at R1, R2, R3. (b) Synthesis of substituted isoellipticines. 
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Certain isoellipticine analogues displayed promising anti-tumour activity 
across a number of different cell lines, particularly leukaemia cell lines (Miller et al, 
2012). Acute myeloid leukaemia (AML) is characterised by a clonal proliferation of 
myeloid precursors with a reduced capacity to differentiate into mature myeloid cells. 
This results in the accumulation of myeloblasts in the bone marrow, peripheral blood 
and spleen. This accumulation of cells disrupts production of normal functional blood 
cells (Preisler & Lyman, 1977). AML accounts for 80% of acute leukaemias in the 
adult population (Handin et al, 2003). Novel therapeutics are urgently needed to treat 
this disease as the success of conventional chemotherapy has been limited. Relapse 
rates of AML patients are high with only 40% of patients younger than 60 years and 
10%–20% of older patients remaining in remission 5 years after diagnosis 
(Lowenberg, 1996). 
Ellipticine functions by a number of mechanisms (Deane et al, 2013). 
Potentially the most extensively examined mechanism of action of ellipticine is its 
interaction with DNA. These interactions include DNA intercalation (Lerman, 1961), 
topoisomerase II inhibition (Ross et al, 1978) bio-oxidation and adduct formation 
(Auclair & Paoletti, 1981). It has also emerged that ellipticines are capable of 
producing mitochondrial damage (Kuo et al, 2005) and inducing endoplasmic 
reticulum stress (Hagg et al, 2004). It is now known that ellipticines inhibit kinases 
such as AKT (Jin et al, 2004), c-Kit (Vendome et al, 2005) and protein kinase CK2 
(Prudent et al, 2010). This inhibition of CK2 activity has been associated with cell 
cycle arrest and apoptosis in human cancer cells (Prudent et al, 2010). In recent years 
it has been suggested that ellipticine interacts with p53 (Peng et al, 2003). p53 
responds to a variety of stresses, including oxidative stress, that leads to genomic 
instability (Liu et al, 2008). In response to DNA damage, or cellular stress, p53 
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activates the transcription of several target genes, including p21. Increased levels of 
p21 result in inhibition of several cyclin-dependent kinase (cdk) complexes causing 
cell cycle arrest. The up-regulated p53 and the subsequent cell cycle arrest lead to 
poly(ADP-ribose) polymerase (PARP) fragmentation and apoptosis. Isoellipticine 
possesses similar anticancer properties to ellipticine, but the mechanism has not been 
investigated in any detail (Miller et al, 2012). We document here the cellular effects 
of a panel of isoellipticine derivatives and in specific 7-hydroxyisoellipticine which 
has anti-cancer potential. 
 
Results 
The FLT3-ITD expressing MV4-11 cell line is a well-established AML cell 
line used in this study. 
  
7-Formylisoellipticine was synthesised via Duff reaction from 
isoellipticine and could be consequently converted to 7-hydroxyisoellipticine (1) by 
means of a Baeyer-Villiger oxidation and hydrolysis (Miller et al, 2012). Compounds 
2 to 9 were synthesised using appropriately N10 substituted isoellipticine derivatives 
as starting materials. 
As the compounds are soluble in Dimethyl Sulfoxide (DMSO), we examined 
the toxicity of DMSO to MV4-11 cells. Figure 3.2 shows the results of this study. 
Optimum solubility of all of the compounds in the panel could be achieved using 
0.5% DMSO. As this concentration is not toxic to the cells we proceeded to use this 
concentration for all subsequent experiments.  
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Figure 3.2. DMSO toxicity in MV4-11 cells. The effect of increasing concentrations of 24 
hour DMSO treatment on MV4-11 cells. The effect on cell number was measured by trypan 
blue exclusion 
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We exploited the fluorescent nature of the compounds to gain an insight into 
how much of each compound permeated the MV4-11 cells. The addition of side 
chains alters the fluorescent intensity of the compounds although they fluoresce in the 
same range (Figure 3.3A). The data suggest that all 9 compounds each infiltrated the 
cells to different extents (Figure 3.3B).   
 
 
 
 
 
 
                               
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
Cmpd 1 Cmpd 2 Cmpd 3 Cpmd 4 Cmpd 5 Cmpd 6 Cmpd 7 Cmpd 8 Cmpd 9 
R
el
a
ti
v
e 
F
L
2
 f
lu
o
re
sc
e
n
c
e 
In
te
n
si
ty
  
Figure 3.3. Spectral characterisation of the panel of isoellipticine derivatives. (a) 
Excitation and emission spectra of each derivative. (b) Relative FL2 detection of MV4-11 
cells incubated with 5 µM of each derivative for 24 hours analysed by flow cytometry. Data 
are corrected for the fluorescence of each derivative. Values are expressed as mean ± SD.  
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Subsequently, the effect of 5 μM of each derivative on the cell cycle of MV4-11 
cells was examined (Figure 3.4). Propidium iodide was used to identify the 
percentage cells in each phase. The nine novel compounds had distinct effects on the 
cell cycle. Compounds 1 and 2 caused a G2/M arrest. Compounds 3-5 increased sub 
G1 phase while compounds 6-9 had no effect on the cell cycle at the given dose.  The 
results from this experiment focused attention on compound 1, 7-
hydroxyisoellipticine due to its evident anti-proliferative properties.  
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A dose response analysis of 7-hydroxyisoellipticine on MV4-11 cells was 
carried out (Figure 3.5A), which demonstrated no effect on the cell cycle at doses 
lower than 2.5 μM. Interestingly, we observed that the G2/M arrest caused by 5 μM is 
greater than at any other dose (Figure 3.5B). When concentrations of the drug 
increase above 5 μM the sub G1 population of cells demonstrated a dose dependent 
increase. The anti-proliferative effect at 5 μM was confirmed by trypan blue exclusion 
assay (Figure 3.5C).  
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Figure 3.5. 5 µM 7-hydroxyisoelliptine causes G2/M cell cycle arrest in MV4-11 cells 
(a) The cell cycle of MV4-11 cells incubated with different doses of 7-hydroxyisoelliptine 
for 24 hours was analysed by propidium iodide staining. A representative profile is shown. 
Values represent the percentage (%) of cells in each cell cycle phase of the cells treated with 
7-hydroxyisoellipticine. (b) Quantification of cell cycle analysis. (c) The effects of 5 µM 7-
hydroxyisoellipticine on cell number measured by trypan blue exclusion. Black line = 5 µM 
7-hydroxyisoellipticine, grey = 0.5 % DMSO control. * = p-value < 0.01. The error bars 
represent ±SD  
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Subsequent to the determination that 5 μM 7-hydroxyisoellipticine caused a 
G2/M arrest in MV4-11 cells we investigated the effects of this dose on the cell cycle 
of 5 other leukaemia cell lines (Figure 3.5). Jurkat, Molt-3 and K652 are all of a 
lymphoblastic morphology. Jurkat is an acute T cell leukaemia cell line, Molt-3 is an 
acute lymphoblastic leukaemia cell line and K562 is a chronic myelogenous 
leukaemia cell line. U937 is a histiocytic lymphoma cell line of a monocytic 
morphology and HL60, a promyelocytic leukaemia cell line that has myloblastic 
morphology. At a concentration of 5 μM, 7-hydroxyisoellipticine caused a G2/M 
arrest in all of these cell lines (Figure 3.6). 
 
 
 
As well as arresting cell cycle, ability to inhibit colony formation is also an 
attractive characteristic of a chemotherapeutic agent.  Colony formation assay is an in 
vitro cell survival assay based on the ability of a single cell to grow into a colony. The 
colony is defined to consist of at least 50 cells. This assay is the method of choice to 
determine the effectiveness of cytotoxic agents (Franken et al, 2006). Figure 3.7 
shows that 5 μM 7-hydroxyisoellipticine can inhibit MV4-11 colony formation. 
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Previously, ellipticine has been shown to elevate intracellular reactive oxygen 
species (ROS) levels (Kim et al, 2011), and so ROS levels post 7-
hydroxyisoellipticine treatment were measured. Dihydroethidium has been used 
extensively in cell culture experiments to evaluate ROS production (Gomes et al, 
2005). 7-Hydroxyisoellipticine (5 μM) resulted in a 62% increase in ROS levels when 
compared to the control (Figure 3.8A). To investigate if this contributes to its 
cytostatic effects we introduced ebselen, a potent scavenger of hydrogen peroxide. 
Figure 3.8B shows that while 5 μM 7-hydroxyisoellipticine alone causes almost 40% 
of cells to arrest in the G2/M phase, less than half this number is affected when 10 μM 
ebselen is added with the 7-hydroxyisoellipticine. This result suggests that 7-
hydroxyisoelliptine can arrest cell cycle partially due to its ability to increase ROS.  
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Figure 3.7. 5 µM 7-hydroxyisoelliptine reduces colony formation. (a) Photograph of 
colonies formed by cells that were treated with either 0.5% DMSO control or 5 µM 7-
hydroxyisoelliptine for 24 hours. (b) Quantification of colony formation. 
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Confocal microscopy was employed to assess cellular accumulation of 7-
hydroxyisoellipticine. After 4 hours, the compound accumulation within the cell can 
be seen (Figure 3.9A). With the knowledge that 7-hydroxyisoelliptine increases ROS, 
we investigated the effects of 5 μM 7-hydroxyisoellipticine on the DNA damage 
response pathway. Immunofluorescence was used to analyse γH2AX, a common 
marker for DNA double strand breaks (DSB) (Figure 3.9B). Results from this 
experiment did not give a conclusive answer as to whether 7-hydroxyisoellipticine 
increases γH2AX. To get a more definitive answer western blotting was used to 
examine expression of γH2AX, p53, p21 Waf1/Cip1 (Figure 3.9C). γH2AX was 
found to increase after just 1 hour of treatment with the greatest increase seen 4 hours 
post treatment. Levels decrease between 4 to 8 hours and return to basal levels by 24 
hours. p53 expression was examined as this tumour suppressor gene is activated by 
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Figure 3.8. 5 µM 7-hydroxyisoelliptine can arrest cell cycle partially due to its ability to 
increase ROS. (a) i. ROS levels were measured by flow cytometry using dihydtroethidium. 
ii. Quantification of ROS levels. Grey = Control, black = 5 µM 7-hydroxyisoellipticine. The 
error bars represent ±SD. (b) The cell cycle of MV4-11 cells incubated with 5 µM 7-
hydroxyisoelliptine for 24 hours was analyzed by propidium iodide staining. The cell cycle of 
MV4-11 cells incubated with 5 µM 7-hydroxyisoelliptine for 24 hours and 10 µM ebselen 1 
hour prior to reading was analyzed by propidium iodide staining. A representative profile is 
shown. Black line =0.5 % DMSO control, Red line = 5 µM 7-hydroxyisoellipticine, Blue line 
= 5 µM 7-hydroxyisoellipticine + 10 µM ebselen. 
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DNA damage (Lakin & Jackson, 1999). Following treatment with 7-
hydroxyisoellipticine, p53 increase begins at 1 hour and continues to accumulate at 
each subsequent time point. In addition to p53, we examined p21 Waf1/Cip1 levels. 
Activated p53 binds to DNA and can trigger the expression of many genes, including 
p21. Western blot analysis showed an increase in p21 at 4 hours, which returned to 
basal levels at later time-points.. 
 
p21 is a potent cyclin-dependent kinase inhibitor. Phospho-cdc2 and cyclin B1 
were also examined as the p21 Waf1/Cip1 protein can bind to and inhibit the activity 
of numerous cyclin-dependent kinase (cdk) complexes (Figure 3.10). One such cdk is 
cdk1, known as cdc2. Cyclin B1 is the regulatory subunit of the cdc2 kinase and is a 
Hoescht 7-Hydroxyisoellipticine  Merge 
γ H2AX 
p53 
p21 Waf1/Cip1 
GAPDH 
GAPDH 
GAPDH 
Ctl 1 h 4 h 8 h 24 h 
Figure 3.9. 5 µM 7-hydroxyisoelliptine activates the DNA damage response pathway (a)  
Cells were treated with 5 µM 7-hydroxyisoellipticine for 4 hours and imaged using Olympus 
FluoView FV1000-ASW confocal microscope. (b) Cells were incubated with 7-
hydroxyisoelliptine for 24 hours and with γH2AX prior to imaging using Olympus FluoView 
FV1000-ASW confocal microscope. (c) Western blot of γH2AX, p53, p21 Waf1/Cip1, 
protein expression in MV4-11 cell treated with 0.5% DMSO control (Ctl) and with 5 µM 7-
hydroxyisoellipticine at 1, 4, 8 and 24 hours respectively using GAPDH as a loading control.  
(a) 
(c) 
Control 7-Hydroxyisoellipticine  (b) 
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protein required for mitotic initiation (Kreis et al, 2014). The progression from G2 
into mitosis is negatively regulated by cdc2 phosphorylation on threonine-14 and 
tyrosine-15 residues. The decrease in cyclin B1 and p-cdc2 can be seen from 8 hours 
onwards (Figure 3.10A). Figure 10B shows a schematic of 7-hydroxyisoellipticines 
mechanism of action.  
 
  
 
CK2 inhibition is another possible reason for cell cycle arrest. To investigate 
this possibility the effect of 7-hydroxyisoellipticine on three CK2 substrates; AKT 
(Girardi et al, 2014), JNK (Meggio & Pinna, 2003) and c-Myc (Meggio 2003) was 
examined. We selected these substrates as they are known to play a role in G2/M cell 
cycle arrest. AKT (Lee et al, 2005) and JNK (Gutierrez et al, 2010) are required for 
G2/M phase transition while deregulation of the proto-oncogene c-Myc causes 
persistent and aberrant cell proliferation (Han et al, 1999). No changes were observed 
in any of the three substrates (Figure 3.11).        
Cyclin'B1'Reduc. on'
Cyclin'B1'
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Cyclin'B1'Reduc. on'
Cyclin'B1'
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Cyclin B1 
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       p-cdc2 
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éDNA Damage 
é p53 
é p21 
Cdc2/Cyclin B1 
G2/M Arrest 
Figure 3.10. 5 µM 7-hydroxyisoelliptine mediates cell cycle arrest by inhibiting cyclin B1 
(a) Western blot of p-cdc2 and cyclin b1 protein expression in MV4-11 cells treated with 
0.5% DMSO control (Ctl) and with 5 µM 7-hydroxyisoellipticine at 1, 4, 8 and 24 hours 
respectively using GAPDH as a loading control. (b) Schematic of 7-hydroxyisoellipticine 
mechanism of action.  
(a) 
(b) 
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The cytostatic effects of 7-hydoxyisoellipticine at 24 hours are now obvious. 
However, we became interested in the compounds ability to kill the cells. Indeed, 48 
hours post treatment the cells treated with 7-hydroxyisoellipticine (5 μM) are 
approximately 20% less viable than the control. Cell death was measured by 
calculating the percentage of cells in the sub G1 phase of the cell cycle (Figure 
3.12A). Treated cells were stained with hematoxylin (Figure 3.12B). The 
condensation and fragmentation of the nucleus suggests that the cell death is mediated 
by apoptosis.  
 
 
 
 
 
 
 
 
Ctl 1 h 4 h 8 h 24 h 
 pAKT 
AKT 
           pJNK 
  c-Myc 
GAPDH 
GAPDH 
GAPDH 
       JNK 
GAPDH 
Figure 3.11. 5 µM 7-hydroxyisoellipticine does not affect selected CK2 substrates in 
MV4-11 cells. Western blot of AKT, Phospho-AKT, JNK, Phospho-JNK and c-Myc protein 
expression in MV4-11 cell treated with 0.5% DMSO control (Ctl) and with 5 µM 7-
hydroxyisoellipticine at 1, 4, 8 and 24 hours respectively using GAPDH as a loading control.  
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Figure 3.12. 5 µM 7-hydroxyisoellipticine causes cell death at 48 hours 
(a) The cell cycle of MV4-11 cells with 5 µM 7-hydroxyisoelliptine for 48 hours was 
analysed by propidium iodide staining. A representative profile is shown. (b) Hematoxylin 
staining of MV4-11 cells.  
Sub G1: 20% 
G2/M: 12% 
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To confirm that apoptosis is the method of cell death induced by 7-
hydoxyisoellipticine we examined the expression of a number of proteins associated 
with apoptosis (Figure 3.13). PARP is a key participant in DNA base excision repair 
and in maintaining genome integrity (Simbulan-Rosenthal et al, 1999). The 
appearance of proteolytic cleavage of the precursor PARP marks the final 
commitment of apoptosis confirming the observation made by hematoxylin staining. 
By 48 hours the treated cells shows increased intensity of the cleaved 89-kDa 
fragment of PARP. Caspase-3 is essential for certain processes associated with the 
dismantling of the cell (Porter et al, 1999). Following treatment with 7-
hydroxyisoellipticine procaspase 3 levels decrease. The cleavage of procaspase 3 
further confirms that cell death is occurring by apoptosis.  
 
     
 
From a clinical perspective it is interesting to note that 7-hydroxyisoellipticine 
also induces apoptosis in primary leukaemia lymphocytes (Figure 3.14). 
 
 
 
 
      p53 
β-Actin 
 Caspase 3 
β-Actin 
Ctl 
Figure 3.14. 7-Hydroxyisoellipticine affects primary leukaemia lymphoblasts. Western 
blot of p53 and caspase 3 in primary leukaemia lymphoblasts treated with 0.5% DMSO 
control (Ctl), 5 µM or 10 µM 7-hydroxyisoellipticine for 24 hours using β-actin as a loading 
control.  
 
5 µM  10 µM  
Ctl 24 h 48 h 
β-Actin 
PARP 
β-Actin 
Procaspase 3 
Figure 3.13. 5 µM 7-hydroxyisoellipticine causes apoptosis at 48 hours. Western blot of 
PARP and caspase 3 protein expression in MV4-11 cells treated with 0.5% DMSO control 
(Ctl) and with 5 µM 7-hydroxyisoellipticine at 24 and 48 hours respectively using β-actin as a 
loading control.  
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Discussion  
The method used to synthesise isoellipticine proved to be efficient for the 
project (Figure 3.1). Although the ‘drying’ stage of the process was sometimes time 
consuming, the method ultimately yielded relatively pure, high quality compounds, 
which were easily dissolved in DMSO.  
Spectral characterisation of the derivatives (Figure 3.3) was an important 
component of this study as it showed that the 9 compounds all infiltrate the cells to 
different extents. For example, compound 2 has a relatively low fluorescent intensity, 
however, it has high relative fluorescence when incubated in MV4-11 cells. It is also 
interesting to note that the ability of the respective compounds to infiltrate the cells 
does not appear to correlate with their potency. Compound 3, arguably the most 
potent compound, has relatively low fluorescence when incubated in MV4-11 cells 
(Figure 3.3B). The knowledge of the flourescent range of the compounds was also 
crucial in selecting assays and probes for subsequent experiments. 
Leukaemia is most often treated by combination therapy. The rationale behind 
the combination studies is that multiple drugs are given simultaneously, each with a 
different mechanism of action, therefore reducing the development of resistance. We 
focused our attention on compound 1, 7-hydroxyisoellipticine as this compound 
displayed the greatest cytostatic activity (Figure 3.4). Indeed 7-hydroxy substitution 
appears to confer more cell cycle activity across the series (Figure 3.4B). A cytostatic 
drug is desirable for use in combination therapy as it has the ability to arrest cells in a 
phase of their cycle. Once these cells are arrested and synchronised they can be 
targeted with a cytotoxic agent, thus maximising cell kill fraction and minimising 
normal cell killing (Villasana et al, 2010). 
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The dose response of 7-hydroxyisoellipticine in MV4-11 cells showed that 5 
μM is the optimum cytostatic dose (Figure 3.5). At this dose it can more than double 
the amount of cells in the G2/M phase. When the dose is increased above 5 μM, the 
cells progressively shift from G2/M into the sub G1 phase. Interestingly, there is little 
difference between the effects of the compound when it is used at 5 μM, 10 μM or 25 
μM. However, when the dose is increased to 50 μM, a significant change in 
cytotoxicity profile of the compound is seen.  
The cell cycle of five other leukaemia cell lines was examined to investigate if 
7-hydroxyisoellipticine’s cytostatic effect was limited to the acute myeloid leukaemia 
cell line or whether it caused a broader cell line response (Figure 3.6). The compound 
had an anti-proliferative effect in all of the cell lines, suggesting that it may be useful 
in other types of leukaemia, not just AML. In addition to possessing anti-proliferative 
properties, 7-hydroxyisoellipticine effectively reduced the colony forming potential of 
MV4-11 cells (Figure 3.7), another desirable attribute of a chemotherapeutic. 
Many chemotherapeutics, including ellipticine (Kim et al, 2011) increase 
oxidative stress in cells (Schumacker, 2006). Several studies have demonstrated that 
ROS causes a G2/M arrest (Thorn et al, 2001) (Chung et al, 2002). Therefore, we 
suspected that 7-hydroxyisoellipticine might stimulate the production of intracellular 
ROS. As hypothesised, the ROS levels did increase post treatment (Figure 3.8). As 
ebselen partially reverses the cytostatic potential of 7-hydroxyisoelipticine, it seems 
that this generation of ROS plays a role in the compounds anti-proliferative effect. 
The fact that it doesn’t completely reverse the cytostatic effect may be due to two 
reasons. Firstly, the compound may function through mechanisms other than 
generating ROS. It is also possible that 10 μM ebelsen isn’t sufficient to scavenge the 
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ROS. However, the combination of 7-hydroxyisoellipticine with a higher dose of 
ebselen was too toxic for the cells.   
The fluorescent nature of 7-hydroxyisoellipticine was taken advantage of to 
study its intracellular accumulation (Figure 3.8A). Experiments with the confocal 
microscope revealed that the compound is taken up in the cell. This is consistent with 
published results on the distribution of ellipticine (Sureau et al, 1993) 
Increased ROS levels can induce DNA damage (Bennett, 2001). As γH2AX is 
one of the most important proteins in the DNA damage response pathway (Fernandez-
Capetillo et al, 2004) this was a first protein of interest. There appears to be a slight 
increase at the one-hour timepoint from the immunofluorescence (Figure 3.9B). The 
results from western blotting (Figure 3.9C) are more conclusive as there is a clear 
increase at the earlier time points, indicating that the induction of the ROS increase 
may be prompted by DNA damage. γH2AX levels drop to basal levels at later time 
points, suggesting that the DNA repair mechanisms of the cells have been induced. 
The response to DNA damage results in either cell cycle arrest, and/or 
apoptosis. p53 is essential in both pathways (Fragkos et al, 2009). Numerous studies 
have reported the involvement of p53 in ellipticine-mediated cytotoxic effect (Ohashi 
et al, 1995) (Sugikawa et al, 1999). The present study found that the expression of 
p53 increased in 7-hydroxyisoellipticine treated MV4-11 cells (Figure 3.9C).  
The expression of p21 Waf1/Cip1 is tightly controlled by p53. p21 directly 
prevents mitosis by inactivating and maintaining the inactive state of mitotic cyclin-
cdk complexes. p21 accumulated after treatment with 7-hydroxyisoellipticine (Figure 
3.9C). Ellipticine has been reported to arrest cell cycle progression by regulating the 
expression of cyclin B1 and phosphorylation of cdc2 in human breast cancer cell lines 
(Kuo et al, 2005). The role of cyclin B1 is to advance the cell from G2 to M phase. 
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Here, the increase of p21 is followed by a marked decrease in p-cdc2 and it’s 
associated cyclin, cyclin B1 (Figure 3.10).  
Kuo et al also reported that ellipticine induces apoptosis. The present study 
shows an increase in PARP and procaspase 3 cleavages (Figure 3.13). These 
cleavages are characteristics of apoptosis (Kuo et al, 2005) (Cohen, 1997). Taken 
together with the visualisation of the treated cells (Figure 3.12) this data suggests that 
7-hydroxyisoellipticine generates apoptosis. 
7-Hydroxyisoellipticine also induces apoptosis in primary leukaemia 
lymphocytes (Figure 3.14). However, as discussed in the introduction, leukaemia is a 
heterogeneous disease. Therefore this cytotoxic effect may not be uniform across all 
patient samples. 
In conclusion, we have shown that 7-hydroxyisoellipticine exerts a potent 
cytostatic effect on leukaemia cells, which ultimately leads to apoptotic cell death. 
Our research suggests that this effect is brought about by an induction of ROS, which 
in turn activates the DNA damage response pathway. 
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7-Formyl-10-methylisoellipticine exerts 
cytotoxicity partially through induction 
of mitochondrial reactive oxygen species 
(ROS) 
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Abstract: 
Miller et al, demonstrated that unlike ellipticine, topoisomerase II appears not 
to be the most important biological target with respect to anti-cancer activity of 
isoellipticines (Miller et al, 2012). Thus, it is likely that this new class of compounds 
function by a unique mechanism of action, which has yet to be fully explained. Cell 
cycle analyses revealed that 7-formyl-10-methylisoellipticine showed the most 
promise with respect to cytotoxic activity. We demonstrated that this compound killed 
cells by apoptosis, which is mediated by an induction of reactive oxygen species 
(ROS). In a cell, mitochondria and NAPDH oxidase (Nox) are the major sources of 
ROS. Previous research in our laboratory has shown that Nox derived ROS is critical 
for cell survival. ROS inhibitors were employed to reveal the origin of the ROS. Our 
study suggests that the compound generates ROS in mitochondria, which ultimately 
leads to its cytotoxic effect. Furthermore, synergistic effects are seen when 7-formyl-
10-methylisoellipticine is used in combination with a Nox inhibitor.  This study 
provides detailed cellular information on the potential use of isoellipticines as 
chemotherapeutic agents. By probing the mechanism of action of this novel 
compound class we have uncovered a potential clinical application in the field of 
adjuvant therapy.  
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Introduction: 
 While the mechanisms of action of ellipticine are well documented, the 
biological activity of isoellipticines has been much less investigated. Interestingly, 
low correlation between results of the topoisomerase II decatenation assay and NCI 
screen throughout the panel suggest that topoisomerase II is not the most important 
biological target with respect to anti-cancer activity in this new class of compounds 
(Miller et al, 2012). It was with this in mind that we began exploring the effects of 7-
formyl-10-methylisoellipticine on MV4-11 cells. 
 Classically chemotherapies were considered to induce death solely through 
apoptotic mechanisms. However, accumulating evidence suggests that tumour cells 
response to chemotherapy is not limited to apoptosis, but also includes other modes of 
death, for example autophagy (Brown & Attardi, 2005). Morphologic characteristics 
of cells undergoing apoptosis include membrane blebbing, shrinkage, chromatin 
condensation, and nucleosomal fragmentation. These cells are recognised by 
neighbouring cells that consume the cells’ remains. As apoptosis has been considered 
the major mechanism of chemotherapy-induced cell death, pathways regulating 
apoptosis are the focus of many preclinical drug discovery investigations (Ricci & 
Zong, 2006).  
 Determination of other modes of cell death has lagged behind. Unlike 
apoptosis, autophagy is not synonymous with cell death. During stress it can promote 
cell adaptation and survival, but under some conditions, cells undergo death by 
excessive autophagy. Autophagy is activated in response to nutrient starvation, 
differentiation, and developmental triggers. It is an adaptive process resulting in 
degradation of intracellular proteins and organelles (Lum et al, 2005). A considerable 
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amount of research in now exploring whether to activate or inhibit this process in a 
chemotherapeutic setting.  
Reactive oxygen species (ROS) is a term that refers to all highly reactive 
oxygen derivatives. This group includes oxygen radicals, such as superoxide (O2
•−
), 
hydroxyl (OH
•
), peroxyl (RO2
•
), and alkoxyl (RO
•
) as well as nonradicals that are 
either oxidising agents or are easily converted into radicals, such as hypochlorous acid 
(HOCl), singlet oxygen (
1
O2), and hydrogen peroxide (H2O2) (Woolley et al, 2013). 
ROS are generated in numerous cellular compartments and by multiple enzymes 
within the cell (Finkel, 2011). It is estimated that approximately 90% of ROS can be 
traced back to the mitochondrion. Aerobic respiration results in the generation of ROS 
as a byproduct of the electron transport chain. Mitochondria generate ATP ultilising 
oxygen. During this process the flow of electrons down the respiratory chain gather at 
complex IV. In this scenario, O2
•− 
is formed when a single electron prematurely 
reduces O2. The major sites of superoxide production are thought to be in complex I 
and complex III of the electron transport chain. The result is release of ROS from 
mitochondria resulting in an intercellular environment of oxidative stress. Many 
cellular organelles and enzymes produce ROS not only as a byproduct, like the 
mitochondria but also as a primary function. In the last decade much research has 
focused on the phagocyte NAPDH oxidases (Nox) generating ROS as its preeminent 
role. These enzymes produce large amounts of ROS to execute their role in host 
defense. The Nox family consists of seven isoforms, Nox1-5 and the Dual oxidase 
(Duox) 1 and 2. The major source of ROS generation is a flavin- and haem- 
containing protein complex that removes electrons from cytosolic NADPH that are 
used to reduce molecular O2 and intentionally producing superoxide. Extracellular 
superoxide can re-enter the cell or become converted to hydrogen peroxide. While 
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mitochondria and Noxs are the best-characterised sources of ROS, a host of other 
enzymes can produce these reactive molecules.  Peroxisomes, cytochrome P-450 
enzymes, lipoxygenases, cyclooxygenases, xanthine oxidase and nitric oxide synthase 
are all capable of producing ROS.  
ROS can act as signalling mediators and as such, redox regulation of the cell 
plays a vital role in the balance between cell survival and death. Redox modifications 
of protein kinases seem to inhibit the survival signalling (Trachootham et al, 2008). 
For example, under oxidative stress, activation of ERK induces cell death (Matsuzawa 
& Ichijo, 2005) while redox modification of the kinases results in down-regulation of 
PI3K/AKT signals and a decrease in survival (Murata et al, 2003).  
Cancer initiation and progression have been linked to oxidative stress by 
increasing DNA mutations or inducing DNA damage, genome instability and cell 
proliferation (Visconti & Grieco, 2009). One of the key characteristics of cancer cells 
compared to the normal cells is a persistent pro-oxidative state that can lead to 
intrinsic oxidative stress (Toyokuni et al, 1995). Several oncogenes commonly 
mutated in different types of leukaemia have been shown to alter cellular levels of 
ROS (Reddy et al, 2011). FLT3-ITD results in an increased concentration of ROS 
which in turn can affect growth and proliferation of leukaemic cells (Sallmyr et al, 
2008). Mutated FLT3-ITD is a potent regulator of survival, proliferative and 
differentiation pathways, all of which are important in the development of leukaemia 
(Gilliland & Griffin, 2002). The presence of FLT3-ITD mutation has been proposed 
to elevate ROS levels through Nox activation (Sallmyr et al, 2008). Conversely, 
Reddy et al. have found that pharmacological inhibition of FLT3-ITD resulted in a 
reduction in mitochondrial superoxide levels. This suggests that mitochondria may be 
the source of the oncogene-induced ROS in leukaemia. Furthermore, this study has 
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demonstrated that Nox-generated ROS, as opposed to mitochondrial ROS, were 
involved in the regulation of cell growth and migration processes in AML cells 
(Reddy et al, 2011).          
 As cancer cells and cancer cell lines have been shown to possess higher levels 
of ROS than their healthy counterparts (Kumar et al, 2008), it is therefore possible 
that ROS production by malignant cells may represent a potential therapeutic target. 
There are two possible approaches to manipulating ROS in malignant cells 
therapeutically. The first approach to targeting ROS in cancer is to use antioxidant 
molecules suppressing the high levels of ROS observed in some cancer cells (Hole et 
al, 2011). Unfortunately, this approach has a number of limitations. Drummond et al 
suggest that the reaction of the targeted ROS with the antioxidant may produce 
another type of ROS that does not react with the original antioxidant (Drummond et 
al, 2011). The second approach is a pro-oxidant approach. By increasing oxidant 
levels this treatment aims to cause catastrophic chemical damage only in those cells 
where oxidative stress was preexistent (Hole et al, 2011).     
   The aims of our work were to determine the type of cell death 
that 7-formyl-10-methylisoellipticine induces. Furthermore, we aimed to evaluate if 
generation of ROS plays a role in this mechanism and investigate the source of this 
ROS. Finally, as FLT3 ITD mutation is associated with elevated ROS, we sought to 
examine the effect of our compound on the activation of this oncogene.  
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Results: 
While chapter 3 focused on 7-hydroxyisoellipticine due to its cytostatic 
effects, this chapter centers on the compound that we believed showed the most 
cytotoxic potential, 7-formyl-10-methylisoellipticine. The cell cycle arresting effects 
of 7-formyl-10-methylisoellipticine were assessed in Figure 4.1A. These data show 
that 5 μM 7-formyl-10-methylisoellipticine arrested almost 40 % of cells in the sub 
G1 phase after 24 hours. This response was confirmed by western blot in Figure 4.1B. 
Cyclin D is involved in regulating cell cycle progression (Yang et al, 2006). It 
interacts with four cyclin dependent kinases (cdks): Cdk2, 4, 5, and 6. Our results 
show that both cyclin D2 and cyclin D3 levels were inhibited by 16 hours and levels 
remained low at 24 hours. Inhibition of cyclin D induces down regulation of cdks. 
These processes lead to an arrest of the cell in G0/G1 stage (Kufe et al, 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. 5 µM 7-formyl-10-methylisoellipticine increases the sub-G1 phase of MV4-11 
cell cycle. (a) The cell cycle of MV4-11 cells incubated with 5 µM 7-formyl-10-
methylisoellipticine for 24 hours was analysed by propidium iodide staining. A representative 
profile is shown. Values represent the percentage (%) of cells in sub G1 phase of cell cycle 
following treatment with 5 µM 7-formyl-10-methylisoellipticine. Black line = 5 µM 7-
formyl-10-methylisoellipticine, grey = 0.5 % DMSO control. (b) Western blot of cyclin D2 
and cyclin D3 protein expression in MV4-11 cell treated with 0.5% DMSO control (Ctl) and 
with 5 µM 7-formyl-10-methylisoellicine at 4, 8, 16 and 24 hours respectively using GAPDH 
as a loading control. * = p-value < 0.05. The error bars represent ±SD. n = 3.  
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MV4-11 cells were treated with a range of concentrations of 7-formyl-10-
methylisoellipticine for 24 hours to evaluate the minimum concentration causing 
significant cytotoxicity. Using the trypan blue exclusion assay this concentration was 
determined as 5 μM (Figure 4.2A). Subsequently, the cytotoxic potential of 5 μM 7-
formyl-10-methylisoellipticine on the cells over a 96 hour time period was examined 
(Figure 2B). Results revealed that the in vitro anti-cancer effect of this compound is 
time-dependent, achieving more than 90% cell death at 96 hours (Figure 4.2B). The 
cytotoxicity of 7-formyl-10-methylisoellipticine was confirmed by western blot. 
Figure 4.2C examines the protein expression of Poly (ADP-ribose) polymerase 
(PARP) and pro-caspase 3 following treatment with 7-formyl-10-methylisoellipticine. 
PARP is mainly involved in DNA repair and programmed cell death (Boulares et al, 
1999). By 16 hours post treatment the treated cells showed increased intensity of the 
cleaved 89-kDa fragment of PARP. Cleavage of the precursor PARP marks the final 
commitment of apoptosis. In addition, caspase 3 plays an essential role in the 
execution of apoptosis (Porter et al, 1999). Similar to PARP cleavage, procaspase 3 
levels were decreased by 16 hours. Taken together these results strongly suggest that 
7-formyl-10-methylisoellipticine induces apoptotic cell death. 
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Bearing in mind that 7-formyl-10-methylisoellipticine appears to induce 
apoptosis we investigated if the compound can also affect autophagy (Figure 4.3). To 
do so, the protein expression of beclin-1, LC3B and p62, three markers of autophagy 
were examined (Figure 3A). Beclin-1 participates in the regulation of autophagy and 
has an important role in development and tumorigenesis (Zhong et al, 2009). At 16 
Figure 4.2. 7-Formyl-10-methylisoellipticine induced apoptosis is dose and time 
dependent. (a) The effects of a range of 7-formyl-10-methylisoellipticine concentrations on 
MV4-11 cells treated for 24 hours, measured by trypan blue exclusion. Black line = 7-
formyl-10-methylisoellicine, grey = 0.5 % DMSO control. (b) The effects of 5 µM 7-
formyl-10-methylisoellipticine on MV4-11 cells treated for 24 to 96 hours, measured by 
trypan blue exclusion. Black line = 5 µM 7-formyl-10-methylisoellicine, grey = 0.5 % 
DMSO control. (c) Western blot of PARP and pro-caspase 3 protein expression in MV4-11 
cell treated with 0.5% DMSO control (Ctl) and with 5 µM 7-formyl-10-methylisoellicine at 
4, 8, 16 and 24 hours respectively using β-actin as a loading control. * = p-value < 0.05. The 
error bars represent ±SD. n = 3.  
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hours post treatment there is a clear decrease in beclin-1 expression and this is 
completely abolished by 24 hours. A similar trend is seen in the expression of LC3B, 
a reliable autophagosome marker for monitoring autophagy (Mizushima et al, 2010), 
with a clear decrease at 16 and 24 hours post treatment. The protein expression of 
these two markers suggests that autophagy is being down regulated. However, 
expression of p62 suggests a conflicting result. Here, a time dependent decrease is 
seen, which begins from just 4 hours. p62 accumulates when autophagy is inhibited, 
and decreased levels can be observed when autophagy is induced (Bjorkoy et al, 
2009). Therefore, western blotting did not give us a conclusive answer as to whether 
7-formyl-10-methylisoellipticine induces or inhibits autophagy. To answer this 
question we employed Giemsa-Wright staining.  Figure 4.3B suggests that autophagy 
is not occurring as apoptotic bodies are present and there is a lack of membrane 
rupture in the treated cells (Liu & Levine, 2015). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. 5 µM  7-formyl-10-methylisoellipticine affects autophagy in MV4-11 cells. (a) 
Western blot of Beclin-1, LC3B and p62 protein expression in MV4-11 cells treated with 
0.5% DMSO control (Ctl) and with 5 µM 7-formyl-10-methylisoellipticine at 4, 8, 16 and 24 
hours respectively using β-actin as a loading control. (b) Giemsa Wright stain of MV4-11 
cells treated with 0.5% DMSO control (Control) or with 5 µM 7-formyl-10-
methylisoellipticine for 24 hours (7F). 
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Ellipticine has been shown to elevate intracellular reactive oxygen species 
(ROS) levels (Kim et al, 2011). As previsouly described, isoellipticine derivative, 7-
hydroxyisoellipticine increased ROS (Russell et al, 2014); however, the source of this 
ROS was unidentified. Mitosox has been used extensively in vitro to evaluate ROS 
production from the mitochondria (Kalyanaraman et al, 2012). We showed that 7-
formyl-10-methylisoellipticine can also increase ROS (Figure 4.4A). Furthermore, we 
used Mitosox to determine if this compound increased mitochondrial ROS (Figure 
4.4B). The data demonstrate that 5 μM 7-formyl-10-methylisoellipticine increased 
mitochondrial ROS more than five fold relative to the control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 To further investigate the source of the 7-formyl-10-methylisoellipticine-
induced ROS we employed ROS inhibitors. Initially three of these inhibiotrs were 
used, each to target one of the three main sources of ROS in the cell. The three 
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Figure 4.4. 5 µM 7-formyl-10-methylisoellipticine increases total and mitochondrial 
reactive oxygen species after 1 hour in MV4-11 cells (a) i. Total ROS levels were measured 
by flow cytometry using dihydtroethidium. ii. Quantification of ROS levels. (b) i. 
Mitochondrial ROS levels were measured by flow cytometry using MitoSox. ii. 
Quantification of ROS levels Grey = Control, black = 5 µM 7-formyl-10-
methylisoellipticine. The error bars represent ±SD. * = p-value < 0.05. n = 3. Background 
fluorescence of  7-formyl-10-methylisoellipticine is accounted for.	
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inhibitors were diphenyleneiodonium (DPI), a NADPH oxidase inhibitor,  diclofenac, 
a cyclooxygenase (COX) inhibitor and rotenone, a mitochondrial complex I inhibitor.  
Figure 4.5 shows the effects of a range of concentrations of these inhibitors on MV4-
11 cells.  
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
A concentration of just 1 μM DPI was sufficient to cause a reduction in ROS 
while the same effect could be achieved using 10 μM diclofenac. However, it is 
curious to note that rotenone failed to reduce ROS at any of the given concentrations.
 In order to achieve mitochondrial ROS inhibition, we recruited two additional 
mitochondrial inhibitors, myxothiazol, an inhibitor of the mitochondrial cytochrome 
bc1 complex and lonidamine, a mitochondrial hexokinase inhibitor. We also reverted 
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Figure 4.5. ROS inhibitors have varied effects on total ROS levels. Quantification of ROS 
levels measured by flow cytometry using DHE. MV4-11 cells were treated with DPI and 
Rotenone 1 hour prior to 5 µM 7F treatment while Diclofenac required a 2 hour pretreatment. 
Measurements were taken 1 hour post 7F treatment. The error bars represent ±SD. n = 3. 
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to the MitoSox probe as we believed this may be more sensitive to changes in 
mitochondrial ROS. Figure 4.6 shows that none of these inhibitors were effective in  
decreasing mitochondrial ROS. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hole et al, have shown that primary human AML blast generate ROS mainly 
from Noxs and not from the mitochondria (Hole et al, 2013). Therefore, we 
hypothesised that in our system, mitochondrial derived ROS are relatively quiescent 
in a normal state and are only elevated and respond to the inhibitors upon induction of 
stress. For example, Naughton & Cotter showed that lonidamine can reduce ROS in 
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Figure 4.6. Mitochondrial ROS inhibitors do not reduce mitochondrial ROS in MV4-11 
cells. Quantification of Mitochondrial ROS levels measured by flow cytometry using 
Mitosox. MV4-11 cells were treated with various concentrations of the inhibitors for 1 hour 
before measurement. The error bars represent ±SD.  
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cells cultured in serum free media (Naughton & Cotter, unpublished). As such we 
proceeded to use these three inhibitors in combination with 7-formyl-10-
methylisoellipticine. The range of concentrations of the inhibitors used initially was 
selected based on the use of these compounds in the literature (Iyer et al, 2009) 
(Naughton & Cotter, unpublished). Figure 4.7 shows the effects of the optimum 
concentration of each of the three inhibitors in combination with 7-formyl-10-
methylisoellipticine on mitochondrial ROS. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
When used in combination with 7-formyl-10-methylisoellipticine all three 
inhibitors are capable of reducing mitochondrial ROS with myxothizol and 
lonidamine even decreasing them to the point of statistical significance. With the 
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Figure 4.7. The increase in mitochondrial ROS caused by 7-formyl-10-methyl-
isoellipticine treatment can be reduced when a mitochondrial ROS inhibitor is used in 
combination. Quantification of Mitochondrial ROS levels measured by flow cytometry 
using Mitosox. MV4-11 cells were treated with of the inhibitors for 1 hour pre-treatment 
followed by a 1 hour treatment with 5 µM 7F prior to measurement. Myzothiazol (Myxo) 
was used at 1 µM, Rotenone (Rot) was used at 5 µM and Lonidamine (Lon) at 100 µM. The 
error bars represent ±SD. * indicates p-value of <0.05. 
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knowledge that these inhibitors can curtail the mitochondrial ROS induced by 7-
formyl-10-methylisoellipticine, we investigated the relevance of this inhibiton on the 
cytotoxicity of the isoellipticine. To do so, we pretreated the MV4-11 cells with the 
inhibitors before subjecting them to a 24 hour treatment with 5 μM 7-formyl-10-
methylisoellipticine. Figure 4.8 shows the results of this experiment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is clear from this result that all three inhibitors are capable of reducing the 
cytotoxic potential of 7-formyl-10-methylisoellipticine. Again it is myxothiazol and 
lonidamine, which produced significant results. Most notable of these is lonidamine, 
which halves the cytoxicity of 7-formyl-10-methylisoellipticine. This reduction in 
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Figure 4.8. Inhibition of mitochondrial ROS increases when used in combination with 7-
formyl-10-methylisoellipticine. Quantification of cell cycle analysis by flow cytometry 
using PI. MV4-11 cells were treated with 1 µM Myxothiazol (Myxo), 5 µM Rotenone (Rot) 
or 100 µM Lonidamine (Lon) for 1 hour followed by a 24 hour treatment with 5 µM 7F prior 
to measurement. The error bars represent ±SD. * indicates p-value of <0.05. 
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cytotoxicity by inhibition of mitochondrial ROS suggests that this isoellipticine 
functions at least partially through increasing mitochondrial ROS.  
To further investigate the generation of mitochondrial ROS in response to 7-
formyl-10-methylisoellipticine, we examined the protein expression of the five 
mitochondrial complexes (Figure 4.9). Altered levels of assembly can arise from 
mutations in individual subunits, mutations in assembly factors for the complexes, 
mtDNA depletion or as a result of physiological and or pathological changes, 
including oxidative stress. Figure 4.9 shows that complex I and complex III are 
decreased by treatment. A reduction in complex III can be seen 4 hours post treatment 
while complex I is diminished from 16 hours post treatment. This result again 
suggests that 7-formyl-10-methylisoellipticine increases mitochondrial ROS as the 
major sites of superoxide production are thought to be complex I and complex III of 
the electron transport chain (Lenaz, 2010). 
  
As 7-formyl-10-methylisoellipticine increases mitochondrial ROS from such 
an early time-point (Figure 4.4) and with this increase in turn playing a role in the 
compounds cytotoxicity, we considered that the compound may localise in the 
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Figure 4.9. 5 µM  7-formyl-10-methylisoellipticine affects mitochondrial complexes in 
MV4-11 cells. Western blot of the 5 OXPHOS complexes protein expression in MV4-11 cell 
treated with 0.5% DMSO control (Ctl) and with 5 µM 7-formyl-10-methylisoellipticine at 4, 
8, 16 and 24 hours respectively using GAPDH as a loading control. 
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mitochondria. To examine this possibility we used confocal microscopy with the 
MitoTracker deep red probe. Figure 4.10 shows that despite the compound’s effect on 
mitochondrial ROS, it does not actually accumulate in the mitochondria. We 
examined this accumulation after 1 hour as this was the time-point that initially 
showed us the increase in mitochondrial ROS (Figure 4.4) 
 
 
 
 
 
 
Although this result was not what we expected, it is possible for a drug to 
stimulate ROS induced pathways without actually localising in the mitochondria. We 
examined the effects of 7-formyl-10-methylisoellipticine on two of these pathways. 
The first pathway we explored was the mitogen-activated protein kinases (MAPK) 
pathway. This pathway is involved in both cell survival and death. Conventional 
MAPKs consist of three family members: the extracellular signal-regulated kinase 
(ERK); the c-Jun NH2-terminal kinase (JNK); and the p38-MAPK (Wada & 
Penninger, 2004), and so the protein expression of these proteins along with the 
associated phosphorylated proteins was examined. Figure 4.11 shows that pERK 
expression is dramatically decreased at 4 hours. By 8 hours it is beginning to increase 
and by 16 hours it is back to basal levels. Decreased ERK signal is associated with 
apoptosis. A subtle increase is seen in pJNK at 16 and 24 hours, while a decrease is 
seen in pp38 at the same time-points. This coordination may be due to the fact that 
JNK and p38 cooperatively participate in apoptosis (Chuang et al, 2000). Overall the 
7F Mitotracker Merge 
Figure 4.10. Confocal microscopy representing the localisation of 7-formyl-10-
methylisoellipticine in live MV4-11 treated cells. The image on the left shows 5 µM 7-
formyl-10-methylisoellipticine only. The image in the middle shows MitoTracker deep red 
while the image on the right shows the lack of colocalisation (merge). The scale bar 
corresponds to 10 µm. 
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results indicate that 7-formyl-10-methylisoellipticine affects the MAPK pathway. 
 
 
 
 
 
 
 
 
 
 
 
The other ROS induced pathway that we examined was the PI3K/AKT 
pathway. Similar to the MAPK pathway, this pathway can also affect both cell cycle 
and apoptosis (Lawlor & Alessi, 2001). Figure 4.12 shows that there is a slight 
decrease in pPI3K from 8 hours, which then remains at this level while a much more 
marked reduction in pAKT is seen from 16 hours. The affect of 7-formyl-10-
methylisoellipticine on this pathway may contribute to its cytotoxic effect as 
inhibition of both pPI3K and pAKT induce cell death (Will et al, 2014). Bad and Bax 
expression was also examined. Bad was the first anti-apoptotic AKT target to be 
identified. The interaction with this target prevents the formation of proapoptotic Bax 
homodimers (McCubrey et al, 2007). Bad expression steadily increases while Bax 
expression initially increases substantially but then decreases. Although 7-formyl-10-
methyisoellipticines effects on pPI3K is subtle, its effects on the activation of the 
other proteins in this pathway leave little doubt that it is being altered by the 
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pERK 
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Figure 4.11. 7-Formyl-10-methylisoellipticine affects the Erk1/2 pathway in MV4-11 
cells. Western blot of pERK, ERK, pJNK, JNK, pp38 and p38 protein expression in MV4-11 
cell treated with 0.5% DMSO control (Ctl) and with 5 µM 7-formyl-10-methylisoellipticine 
at 4, 8, 16 and 24 hours respectively using β-actin or GAPDH as a loading control.  
Ctl 4 h 8 h 16 h 24 h 
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compound. 
 
 
 
 
 
 
 
 
 
 
 Although all of the results so far are indicative of 7-formyl-10-
methylisoellipticine generating ROS from the mitochondria, it is possible for ROS to 
be produced from more than one source. Therefore we also investigated the 
possibility of 7-formyl-10-methylisoellipticine generating ROS from COXs and Noxs, 
two other major sources of ROS in the cell. To do so we again used the inhibitors that 
were optimised in Figure 4.5 in combination with 7-formyl-10-methylisoellipticine. 
Figure 4.13 shows the effect of the compound in combination with diclofenac. It can 
be seen that the addition of the inhibitor makes no difference to the ROS generated by 
the compound (Figure 4.13A). Furthermore, when the cells are pretreated with 
diclofenac before treatment with 7-formyl-10-methylisoellipticine, the cytotoxicity of 
the compound is not affected. These results suggest that 7-formyl-10-
methylisoellipticine does not generate COX derived ROS. 
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 PI3K 
AKT 
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Figure 4.12. 7-Formyl-10-methylisoellipticine affects the PI3K/AKT pathway in MV4-11 
cells. Western blot of pPI3K, PI3K, pAKT, AKT, Bax and Bad protein expression in MV4-11 
cell treated with 0.5% DMSO control (Ctl) and with 5 µM 7-formyl-10-methylisoellipticine 
at 4, 8, 16 and 24 hours respectively using β-actin as a loading control.  
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The final source of ROS to be assessed was Noxs. To determine their role in 
7-formyl-10-methylisoellipticine mechanism of action, DPI was employed (Figure 
4.14). Addition of DPI to the 7-formyl-10-methylisoellipticine treatment resulted in 
more than double the amount of ROS being produced relative to 7-formyl-10-
methylisoellipticine treatment alone (Figure 4.14A). This suggested that 7-formyl-10-
methylisoellipticine does not generate Nox derived ROS as surely if the said 
generated ROS were originating from Nox, Nox inhibition would lead to a decrease, 
not an increase in the level of ROS produced. We also looked at the effect on 
cytotoxicity when the two agents are used in combination (Figure 4.14B). The effect 
of this combination is a significant increase in cytotoxicity compared to the 
cytotoxicity of the 7-formyl-10-methylisoellipticine alone. This result again suggests 
that 7-formyl-10-methylisoellipticine-induced ROS do not originate from Nox.  
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Figure 4.13. Inhibition of COX derived ROS does not affect total ROS levels or viability 
when used in combination with 7-formyl-10-methylisoellipticine. (a) Quantification of 
ROS levels measured by flow cytometry using DHE. MV4-11 cells were treated with 10 µM 
for 1 hour followed by a 1 hour treatment with 5 µM 7F prior to measurement. (b) 
Quantification of cell cycle analysis by flow cytometry using PI. MV4-11 cells were treated 
with 10 µM diclofenac for 2 hours followed by a 24 hours treatment with 5 µM 7F prior to 
measurement. The error bars represent ±SD. * indicates p-value of <0.05. 
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The final component of 7-formyl-10-methylisoellipticine’s mechanism 
of action that we investigated was its ability to inhibit FLT3, one of the most 
frequently mutated genes in AML (Figure 4.15A). To do so we used 32D 
cells, a myeloblast-like cell line transfected with FLT3-ITD, the most common 
mutation in AML (Stirewalt & Radich, 2003). Figure 4.15A shows that 5 μM 
7-formyl-10-methylisoellipticine can arrest these cells in the G2/M phase of 
the cell cycle. We also examined the effect of the same concentration of this 
compound on FLT3 expression in this cell line. Figure 4.15B demonstrates 
that the compound is capable of inhibiting phosphorylation of FLT3. 
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Figure 4.14. Inhibition of NOX derived ROS does increase total ROS levels and 
decreases viability when used in combination with 7-formyl-10-methylisoellipticine. (a) 
Quantification of ROS levels measured by flow cytometry using DHE. MV4-11 cells were 
treated with 10 µM for 1 hour followed by a 1 hour treatment with 5 µM 7F prior to 
measurement. (b) Quantification of cell cycle analysis by flow cytometry using PI. MV4-11 
cells were treated with 10 µM for 1 hour followed by a 24 hour treatment with 5 µM 7F prior 
to measurement. The error bars represent ±SD. * indicates p-value of <0.05. 
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Figure 4.15. 7-Formyl-10-methylisoellipticine can inhibit pFLT3. (a) The cell cycle of 
32D ITD cells incubated with 5 µM 7-formyl-10-methylisoellipticine or 0.5% DMSO control 
for 24 hours was analysed by propidium iodide staining of nuclei and flow cytometry. Values 
represent the percentage (%) of cells in each cell cycle phase of the cells treated with 7-
formyl-10-methylisoellipticine. Black line = 5 µM 7-hydroxyisoellipticine, grey = 0.5 % 
DMSO control. (b) Western blot of pFLT3 and FLT3 protein expression in 32D ITD cells 
treated with 0.5% DMSO control (Ctl) and with 5 µM 7-formyl-10-methylisoellipticine for 
24 hours using β-actin as a loading control.  
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Discussion: 
Isoellipticines have been shown to induce oxidative stress and arrest cell cycle 
(Russell et al, 2014). Both of these properties will be valuable in combating AML. It 
is hoped that the surge in ROS levels will cause catastrophic damage to cancer cells 
which possess preexisting high ROS levels, while arresting the cell cycle will inhibit 
the enhanced proliferation, which characterises the disease. As such, this class of 
compounds may have a potential clinical application. 
 In order for a cell to divide successfully, it must undergo each phase of the cell 
cycle. The machinery controlling the mammalian cell cycle consists of cdks, which 
are activated by association with cyclin regulatory subunits. Targeted cancer therapies 
aim to interrupt a specific component of the complex signalling pathways that result 
in uncontrolled cell proliferation (Aleem & Arceci, 2015). Figure 4.2A shows that 5 
μM 7-formyl-10-methylisoellipticine led to an accumulation of cells in the Sub G1 
phase. Cyclin D is required for activation of cell cycle entry (Yang et al, 2006). It is 
shown in Figure 4.3B that from 16 hours 5 μM 7-formyl-10-methylisoellipticine 
inhibited this subunit. The knowledge that isoellipticines suppress this component of 
the cell cycle apparatus may be beneficial for designing more targeted therapy. 
 Figure 4.3 highlights the cytotoxicity of 7-formyl-10-methylisoellipticine in 
MV4-11 cells. Figure 4.3A shows that a significant cytotoxic effect can be achieved 
using 5 μM 7-formyl-10-methylisoellipticine for 24 hours. Following on from this 
result we examined the cytotoxicity of 5 μM 7-formyl-10-methylisoellipticine over a 
time course of 96 hours (Figure 4.3B), indicating that the compound can achieve an 
anti-proliferative effect in a time-dependent manner. As we previously showed that 7-
hydroxyisoellipticine induces apoptosis (Russell et al, 2014), we were not surprised to 
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find that 7-formyl-10-methylisoellipticine also activates apoptosis (Figure 4.3C).  
Although the data in Figure 4.3 does strongly suggest that apoptosis is the 
mode of 7-formyl-10-methylisoellipticine cell death, accumulating evidence suggests 
that tumour cell response to chemotherapy is not confined to apoptosis but also 
includes other types of death. Alternative modes of programmed cell death include 
necroptosis and autophagy. While necroptosis is largely associated with inflammatory 
disorders the role of autophagy in cancer and in the response to chemotherapeutic 
agents is now gaining attention. A number of studies have reported that autophagy is 
activated in cancer cells in response to various anticancer therapies (Levine & Yuan, 
2005). Beclin-1 and LC3B are accepted biomarkers for occurrence of autophagy in 
biological samples (Meyer et al, 2013). Their reduced expression, which is shown in 
Figure 4.4A suggests 7-formyl-10-methylisoellipticine down regulates autophagy. 
This lack of autophagy was confirmed by microscopy in Figure 4.4B. It is possible 
that caspase-mediated cleavage of beclin 1 is promoting crosstalk between apoptosis 
and autophagy in response to 7-formyl-10-methylisoellipticine treatment (Kang et al, 
2011). To determine if the compound induces apoptosis and this inhibits the 
autophagy or whether it is capable of directly inhibiting autophagy, more detailed 
analyses using shorter time-points would be required. In order for novel 
chemotherapeutic combinations to succeed, a deeper understanding of how a given 
chemotherapy affects all of the signalling pathways involved in cell death is needed. 
Using this knowledge, attempts must be made to predict whether drug actions will be 
synergistic or antagonistic based on the status of the molecules and the pathways 
being targeted (Ricci & Zong, 2006).       
  It has been proposed that some current mainstay cancer therapies, such 
as daunorubicin may rely on their ability to increase ROS to exert their full cytotoxic 
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effect (Mansat-de Mas, 1999). This is possible as the highly stressed state of 
malignant cells may partly explain the selectivity of these cytotoxic drugs (Benhar et 
al, 2002). Several compounds with pro-oxidant capacity appear to be effective against 
both leukaemic cell lines and primary leukaemic blasts (Hole et al, 2011). As 
previsouly described, isoellipticine derivative, 7-hydroxyisoellipticine increased ROS 
(Russell et al, 2014); however, the origin of this ROS was unidentified. The source of 
7-formyl-10-methylisoellipticine induced ROS was of importance to us as detailed 
knowledge in this area may be advantageous when designing adjuvant therapy.      
 The mechanism of ROS generation from several chemotherapeutics may be 
mitochondrial ROS (Kinder et al, 2010) and so it was of great interest to us when 7-
formyl-10-methylisoellipticine increased mitochondrial derived ROS (Figure 3.5). 
When ROS inhibitors were used to target each of the three main sources of ROS in 
the cell to confirm the mitochondria as the source, not all of the inhibitors achieved a 
reduction in ROS (Figure 4.5). While treatment with DPI, a Nox inhibitor and 
diclofenac, a cyclooxygenase (COX) inhibitor, respectively resulted in a decrease in 
ROS levels, rotenone, a mitochondrial complex I inhibitor failed to do the same. 
While it is known that inhibition of reverse electron transport by rotenone decreases 
ROS production (Votyakova & Reynolds, 2001), results presenting the contrary have 
been reported in other publications (Li et al, 2003). It was therefore necessary to 
employ two additional mitochondrial ROS inhibitors, myxothiazol and lonidamine. 
Still, these inhibitors were also insufficient blockers of mitochondrial ROS (Figure 
4.6). But, as primary human AML blast generate ROS mainly from Noxs and not 
from the mitochondria (Hole et al, 2013) and elevated mitochondrial ROS is a stress 
response (Barbour & Turner, 2014), we hypothesised mitochondrial derived ROS are 
relatively quiescent in a normal state and are only elevated and respond to the 
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inhibitors upon induction of stress.       While 
previous studies in our laboratory used serum free medium as a stress-induced system 
for the cells (Naughton & Cotter, unpublished), our treatment of the cells with 7-
formyl-10-methylisoellipticine is sufficient to cause cellular stress (Russell et al, 
2014). Indeed, when the inhibitors are used in combination with 7-formyl-10-
methylisoellipticine there is a reduction in ROS compared to treatment with 7-formyl-
10-methylisoellipticine alone (Figure 4.7). These data suggest that in MV4-11 cells, 
mitochondrial derived ROS are relatively indifferent in a normal state and are only 
elevated in response to stress. 
To establish if the potency of 7-formyl-10-methylisoellipticine is dependent 
on its augmentation of mitochondrial ROS the cells were treated with the combination 
of the compound and mitochondrial inhibitors and the cytotoxic effect of this 
treatment was compared to treatment with the compound alone. The rationale here 
was that if the induction of mitochondrial ROS are necessary for the compound to 
exert its effects, then addition of the inhibitor would diminish its effects. However, if 
mitochondrial ROS do not play a role in the compounds function, then the addition of 
a mitochondrial inhibitor should make little difference and if anything may increase 
cytotoxicity as it may be inhibiting a survival pathway. Figure 4.8 shows that all three 
inhibitors are capable of reducing the cytotoxic potential of 7-formyl-10-
methylisoellipticine. This reduction in cytotoxicity by inhibition of mitochondrial 
ROS suggests that this isoellipticine functions at least partially through increasing 
mitochondrial ROS and again reinforces the theory that 7-formyl-10-
methylisoellipticine induces mitochondrial derived ROS. It is likely that the 
compound also functions through an additional mechanism of action as even in 
combination with lonidamine, 7-formyl-10-methylisoellipticine still manages to bring 
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about approximately 20 percent cell death. However, it is possible that this is simply 
because the two compounds in combination are too toxic for the cells or because the 
lonidamine could not sufficiently reduce the 7-formyl-10-methylisoellipticine induced 
mitochondrial ROS to basal levels. 
Given that 7-formyl-10-methylisoellipticine elevates mitochondrial ROS we 
investigated if the compound has a physical effect on mitochondria. In Figure 4.9, 
which shows the effect of 5 μM 7-formyl-10-methylisoellipticine on the protein 
complexes involved in oxidative phosphorylation, a change can be seen in complex 
complex III and I. These complexes are known to induce production of toxic reactive 
oxygen species. The decreases seen in these complexes following treatment is 
interesting as agents which inhibit Oxphos have been shown to have anti-tumour 
activity (Abou-Khalil et al, 1985). Defects of complex V are a cause of mitochondrial 
dysfunction (www.abcam.com). No change is seen is complex V post treatment. 
These data suggest that while 7-formyl-10-methylisoellipticine increases 
mitochondrial ROS it does not alter the functioning of the mitochondria directly. We 
were surprised to discover that the compound does not localise in the mitochondria 
given the impact it has on mitochondrial ROS (Figure 4.10). However, this does 
strengthen the hypothesis that 7-formyl-10-methylisoellipticine does not alter the 
functioning of the mitochondria directly. Furthermore, it is possible for the compound 
to indirectly affect mitochondrial-signalling pathways through the ROS that it 
produces.  
Mitochondrial-derived reactive oxygen species have increasingly been 
appreciated to function as signalling molecules (Sullivan & Chandel, 2014). The first 
ROS induced pathway to be examined was the ERK/JNK/p38 cascade. 7-Formyl-10-
methylisoellipticine causes ERK dephosphorylation and induces p38 MAPK and JNK 
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phosphorylation (Figure 4.11). These MAPK play key roles in stress-induced cell 
death (Chen et al, 2008). The deactivation of ERK by 7-formyl-10-
methylisoellipticine is notable as ERK inhibitors are being explored as anticancer 
agents (Johnson & Lapadat, 2002). 
The second ROS induced pathway to be studied was the PI3K/AKT pathway 
(Figure 4.12). The relationship between ROS generation and AKT activation is 
diverse. Extensive studies have found that AKT and ROS could interact with each 
other in the PI3K/AKT signalling pathway (Nakanishi et al, 2014). In this study, 
while little change was seen in the expression of pPI3K, the expression level of p-
AKT significantly decreased following 16 hours of treatment with 7-formyl-10-
methylisoellipticine. As the compound generates ROS as soon as one hour after 
treatment (Figure 4.4) and the change in pAKT is seen much later, it suggests that the 
generation of ROS is the upstream of AKT and that could inhibit the PI3K/AKT 
signalling pathway. This phenomenon has also been reported in other studies. Similar 
results were also found in several anti-cancer agents (cisplatin, resveratrol, tetrandrine 
etc.), which act as suppressors of AKT pathway leading to apoptosis via generation of 
ROS (Liu et al, 2011).        
 In addition to the mitochondrion, COX and Nox were also investigated as 
possible sources of ROS production in response to 7-formyl-10-methyisoellipticine. 
Our results indicate that these cellular components do not contribute to isoellipticine-
induced ROS (Figures 4.13 & 4.14). Furthermore, the observation that Nox inhibition 
actually adds to the cytotoxicity of 7-formyl-10-methylisoellipticine (Figure 4.14) 
reinforces data previously published in our lab that shows that Nox derived ROS 
contribute to cell survival signalling (Groeger et al, 2009). The synergistic effect that 
7-formyl-10-methylisoellipticine produced when used with a Nox inhibitor is relevant 
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from the adjuvant therapy perspective and this will be explored further in the next 
chapter.          
 The presence of FLT3-ITD mutation has been proposed to elevate ROS levels 
through Nox activation (Sallmyr et al, 2008). Figure 4.15 shows that 7-formyl-10-
methylisoellipticine can inhibit pFLT3 in 32D cells transfected with the ITD 
mutation. Assuming that the compound functions the same in these cells as it does in 
the MV4-11 cell line, this could mean that ROS generated from Nox result in survival 
of the cells while ROS generated from mitochondria cause harm to the cells. 
However, Reddy et al. have found that pharmacological inhibition of FLT3-ITD 
resulted in a reduction not an increase in mitochondrial superoxide levels (Reddy et 
al, 2011). To fully elucidate the effect of pFLT3 inhibition on ROS levels more 
extensive time-points for ROS measurement, viability and pFLT3 inhibition are 
required. In this experiment the two later variables are measured at the same time-
point of 24 hours. It is therefore impossible to decipher if the pFLT3 inhibition is 
contributing to the cytotoxicity of the compound in this cell line. Nonetheless, it is 
noteworthy that 7-formyl-10-methylisoellipticine is capable of inhibiting activation of 
this potent regulator of survival. 
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Abstract 
 
Chemotherapeutic drugs are most effective when given in combination. The 
rationale for combination chemotherapy is to use drugs that work by different 
mechanisms, thereby decreasing the likelihood of resistance. Additionally, when 
drugs with different effects are combined, each drug can be used at its optimal dose, 
reducing side effects. We showed, using specialised software, that 7-formyl-10-
methylisoellipticine has synergistic effects when used in combination with the 
clinically used AML drug, daunorubicin, as well as other inhibitors. Furthermore, this 
derivative displayed promising in vivo results. Treatment resulted in a lack of toxicity, 
as mesured by body weight changes and liver enzyme analyses. Most importantly, 7-
formyl-10-methylisoellipticine demonstrated potent anti-tumour activity in the in vivo 
model, implying the potential of isoellipticines as novel chemotherapeutic agents in 
the treatment of leukaemia. Our study documents for the first time, the therapeutic 
potential of an isoellipticine compound in a subcutaneous AML cell-derived 
xenograft (CDX) model. We anticipate that the recent research on ellipticine 
derivatives, such as in this study, will lead the development of an ellipticine analogue 
that may be employed clinically.  
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Introduction 
 Treating AML is challenging. The most commonly used induction regimens 
for AML involve a combination of cytarabine (Ara-C) and either daunorubicin or 
idarubicin. The rationale for combination chemotherapy is firstly, tumour cell 
heterogeneity and its implication for drug resistance, and secondly, the success of 
combination chemotherapy in the clinic (Frei & Eder, 2003). Additionally, advantages 
to combination therapy over a single agent include increasing the number of cells 
exposed to cytotoxic effects and decreasing the incidence and severity of side effects 
of therapy (Pinto et al, 2011). 
The terms ‘additive’, ‘synergistic’ and ‘antagonistic’ are commonly used 
clinically in relation to combination therapy; however, they are not well defined (Frei 
& Eder, 2003). Additive interaction means the effect of two chemicals is equal to the 
sum of the effect of the two chemicals taken separately. Synergistic interaction means 
that the effect of two agents taken together is greater than the sum of their separate 
effect at the same doses, while antagonistic interaction means that the effect of two 
chemicals is less than the sum of the effect of the two drugs taken independently of 
each other. Computer software for PCs developed by Chou and Martin uses both the 
median-effect equation and the combination index equation and can be used for 
multiple drug combinations. This software, called CompuSyn, was set up with the 
intention of promoting pharmacodynamic research and simple computerised 
analytical simulation. A theoretical article describing the concept of combination 
index (CI) and its algorithm, used by this software, has been referenced in over 600 
journals (Chou, 2006). This software defines an additive effect as the combined effect 
predicted by the mass-action law principle in the absence of synergism or antagonism 
(CI=1). Antagonism is defined as a smaller than expected additive effect based on the 
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mass-action law (CI >1). Finally, synergism is considered as a greater than expected 
additive effect based on the mass-action law (CI < 1) (Chou, 2006).  
Human immortal cell lines, such as the MV4-11 cell line used in this work 
have been an invaluable tool in examining cancer biology and analysing the efficacy 
of anticancer drugs (Kashyap et al, 2011). However, culture systems cannot replicate 
the interactions between leukaemia cells and their environment. These models also 
fail to mimic the invasiveness and angiogenesis in AML (Tzukerman et al, 2003). To 
overcome these limitations, murine xenograft models have been developed to allow 
engraftment of primary patient samples and cell lines.  
 
 
 
 
 
 
 
Since the 1930’s, murine models have been used to study AML. The initial 
carcinogen-induced transplantable models evolved to the modern transgenic, 
xenograft, and mosaic approaches (Cook & Pardee, 2013). This evolution of the 
murine model system has been critical to our comprehension and treatment of AML. 
Severe combined immunodeficient (SCID) mice were first described in 1983 (Bosma 
Figure 5.1. Photograph of the AML cell-derived xenograft (CDX) model used in this 
study.   
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et al, 1983). SCID mice exhibit an autosomal recessive mutation of chromosome 16, 
resulting in disruption of the protein kinase DNA-activated catalytic polypeptide 
(Prkdc) gene. This results in deactivation of a DNA recombinase enzyme and an 
inability to express rearranged antigen receptors. The consequence of this is innate 
deficiency in humoral and cellular immunity, with SCID mice lacking functional T 
and B lymphocytes (Bosma et al, 1991). The first human stem cell engraftment into a 
SCID mouse was reported in 1988 (McCune et al, 1988). Xenograft models have the 
unique advantage of being able to explore human cell specific biology in an in vivo, 
albeit immunocompromised environment (Cook & Pardee, 2013). 
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Results:          
 As chemotherapy drugs are frequently more effective when given in 
combination, we examined the cytotoxicity of 7-formyl-10-methylisoellipticine when 
administered simultaneously with other agents. The effect of the combinations was 
determined using the well-established ‘CompuSyn’ software. Before the software can 
analyse the effect of the combination, the ED50 of each drug must be determined. The 
ED50, or ‘median effective dose’ can be defined as the dose that brings about the 
‘desired effect’ in 50% of the population being treated. In this case the ‘desired effect’ 
is cell death. The manufacturers recommend that ¼ ED50, ½ ED50, ED50, 2 x ED50 
and 4 x ED50 of each drug is used in the combination. However, as the DMSO 
control had to be a maximum concentration 0.5% (Figure 3.2), 2 x ED50 and 4 x 
ED50 could not be used for some combinations.  
The first drug we used in combination was cytarabine (Ara-C). Ara-C is a 
deoxycytidine analog that is actively metabolised to arabinofuranosylcytidine 
triphosphate (ara-CTP) (Karanes et al, 1999). It intereferes with DNA synthesis and is 
the main drug used in AML induction therapy. Our results showed that 7-formyl-10-
methylisoellipticine has antagontistic effects when used in combination with Ara-C. 
(Figure 5.2)  
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 The antagonistic effects between the two agents suggest that they function by 
similar mechanisms of action. As Ara-C shows synergy when used with daunorubicin, 
an anthracycline, we suspected that 7-formyl-10-methylisoellipticine would yield 
similar synergic effects. Indeed, this proved to be the case. These 2 cytotoxic 
compounds resulted in synergistic killing at all of the given doses, with the most 
synergistic results being achieved when 7-formyl-10-methylisoellipticine was given at 
½ ED50 and ED50 (Figure 5.3).  
 
 
Figure 5.2. 7-Formyl-10-methylisoellipticine has antagonistic effects when used in 
combination with cytarabine. ED50 values were determined using the trypan blue 
exclusion assay following treatment of MV4-11 cells for 24 hours with the compounds. The 
combination index (CI) at various dose effects was calculated using the median effect 
method. CI values less than 1 indicate synergy; CI of 1 indicates an additive effect; and CI 
greater than 1 demonstrates antagonism between the 2 agents. 
!
7#Formyl#10#methylisoellipticine!(7F)!
ED50 status Concentration (µM) 
¼ ED50 2.8 
½ ED50 5.5 
ED50 11 
2 ED50 22 
 
Cytarabine (Ara-C) 
ED50 status Concentration (µM) 
¼ ED50 19 
½ ED50 38 
ED50 75 
2 ED50 150 
 
7F + Ara-C 
ED50 status Combination Index (CI) 
¼ ED50 7F + ¼ ED50 Ara-C 0.87 
¼ ED50 7F + ½ ED50 Ara-C 1.18 
¼ ED50 7F + ED50 Ara-C 1.78 
¼ ED50 7F + 2 ED50 Ara-C 3.31 
½ ED50 7F + ¼ ED50 Ara-C 0.75 
½ ED50 7F + ½ ED50 Ara-C 1.1 
½ ED50 7F + 1 ED50 Ara-C 1.5 
½ ED50 7F + 2 ED50 Ara-C 1.9 
ED50 7F + ¼ ED50 Ara-C 1.7 
ED50 7F + ½ ED50 Ara-C 2.1 
ED50 7F + ED50 Ara-C 2.7 
ED50 7F + 2 ED50 Ara-C 3.5 
2 ED50 7F + ¼ ED50 Ara-C 2.6 
2 ED50 7F + ½ ED50 Ara-C 4.3 
2 ED50 7F + ED50 Ara-C 5 
2 ED50 7F + 2 ED50 Ara-C 6 
!
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Following the examination of 7-formyl-10-methylisoellipticine in combination 
with clinically used chemotherapeutics, we drew on what we had learned about the 
compound in chapter 4 and based the subsequent combinations on the hypothesised 
mechanism of this isoellipticine. The main observation from this chapter was that 7-
formyl-10-methylisoellipticine functions partially through increasing mitochondrial 
ROS. Therefore, we suspected that if the compound needs to produce ROS to exert its 
effects, then an antioxidant should diminish its cytotoxicity. We selected butylated 
hydroxyanisole as the antioxidant to use in combination as it is widely used for its 
Figure 5.3. 7-Formyl-10-methylisoellipticine has synergistic effects when used in 
combination with daunorubicin. ED50 values were determined using the trypan blue 
exclusion assay following treatment of MV4-11 cells for 24 hours with the compounds. The 
combination index (CI) at various dose effects was calculated using the median effect 
method. CI values less than 1 indicate synergy; CI of 1 indicates an additive effect; and CI 
greater than 1 demonstrates antagonism between the 2 agents. 
7"Formyl"10"methylisoellipticine3(7F)3
ED50 status Concentration (µM) 
¼ ED50 2.8 
½ ED50 5.5 
ED50 11 
2 ED50 22 
 
Daunorubicin (DR) 
ED50 status Concentration (nM) 
¼ ED50 0.7 
½ ED50 1.5 
ED50 2.9 
2 ED50 5.8 
4 ED50 11.6 
 
7F + DR 
ED50 status Combination Index (CI) 
¼ ED50 7F + ¼ ED50 DR 0.1 
¼ ED50 7F + ½ ED50 DR 0.1 
¼ ED50 7F + ED50 DR 0.1 
¼ ED50 7F + 2 ED50 DR 0.1 
¼ ED50 7F + 4 ED50 DR 0.02 
½ ED50 7F + ¼ ED50 DR 0.03 
½ ED50 7F + ½ ED50 DR 0.02 
½ ED50 7F + 1 ED50 DR 0.02 
½ ED50 7F + 2 ED50 DR 0.04 
½ ED50 7F + 4 ED50 DR 0.04 
ED50 7F + ¼ ED50 DR 0.03 
ED50 7F + ½ ED50 DR 0.03 
ED50 7F + ED50 DR 0.04 
ED50 7F + 2 ED50 DR 0.05 
ED50 7F + 4 ED50 DR 0.05 
2 ED50 7F + ¼ ED50 DR 0.06 
2 ED50 7F + ½ ED50 DR 0.06 
2 ED50 7F + ED50 DR 0.07 
2 ED50 7F + 2 ED50 DR 0.7 
2 ED50 7F + 4 ED50 DR 0.8 
3
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antioxidant properties (Singh et al, 2013). Our results showed that these two 
compounds have antagonistic effects except when both of them are used above their 
ED50 concentrations (Figure 5.4). This again reinforces that isoellipticines 
cytotoxicity depends on their ability to stimulate the production of ROS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In chapter 4 we also postulated that the production of ROS, induced by 7-
formyl-10-methylisoellipticine, stimulated the JNK signalling pathway. To determine 
if this pathway is critical to the compounds mechanism of action we employed an 
inhibitor of this pathway, SP600125. As well as this inhibitor acting as a useful tool 
for our mechanistic investigation, it is also being investigated as an anticancer agent 
(Jemaa et al, 2012), and so this combination is also relevant form a clinical 
perspective. Our data showed that once 7-formyl-10-methylisoellipticine is used at or 
Figure 5.4. 7-Formyl-10-methylisoellipticine has a range of effects when used in 
combination with butylated hydroxyanisole. ED50 values were determined using the 
trypan blue exclusion assay following treatment of MV4-11 cells for 24 hours with the 
compounds. The combination index (CI) at various dose effects was calculated using the 
median effect method. CI values less than 1 indicate synergy; CI of 1 indicates an additive 
effect; and CI greater than 1 demonstrates antagonism between the 2 agents. 
7-Formyl-10-methylisoellipticine (7F) 
ED50 status Concentration (µM) 
¼ ED50 2.8 
½ ED50 5.5 
ED50 11 
 
Butylated hydroxyanisole (BHA) 
ED50 status Concentration (µM) 
¼ ED50 50 
½ ED50 100 
ED50 200 
2 ED50 400 
 
7F + BHA 
ED50 status Combination Index (CI) 
¼ ED50 7F + ¼ ED50 BHA 1.027 
¼ ED50 7F + ½ ED50 BHA 0.844 
¼ ED50 7F + ED50 BHA 0.989 
¼ ED50 7F + 2 ED50 BHA 1.413 
½ ED50 7F + ¼ ED50 BHA 0.908 
½ ED50 7F + ½ ED50 BHA 1.290 
½ ED50 7F + ED50 BHA 1.343 
½ ED50 7F + 2 ED50 BHA 0.589 
ED50 7F + ¼ ED50 BHA 3.077 
ED50 7F + ½ ED50 BHA 1.349 
ED50 7F + ED50 BHA 0.301 
ED50 7F + 2 ED50 BHA 0.594 
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above ½ ED50, these 2 compounds had synergy in MV4-11 cells (Figure 5.5). This 
suggests that the JNK pathway is not essential for 7-formyl-10-methylisoellipticines 
cytotoxicity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The final drug that we used in combination was diphenyleneiodonium (DPI), a 
Nox inhibitor. Our study revealed that these compounds have strong synergy. A CI 
value of less than one was calculated for every single dose combination (Figure 5.6). 
This synergy suggests that the MV4-11 need fully function Nox to survive. 
   
 
 
 
Figure 5.5. 7-Formyl-10-methylisoellipticine has mainly synergistic effects when used in 
combination with SP600125. ED50 values were determined using the trypan blue exclusion 
assay following treatment of MV4-11 cells for 24 hours with the compounds. The 
combination index (CI) at various dose effects was calculated using the median effect 
method. CI values less than 1 indicate synergy; CI of 1 indicates an additive effect; and CI 
greater than 1 demonstrates antagonism between the 2 agents. 
 
7"Formyl"10"methylisoellipticine3(7F)3
ED50 status Concentration (µM) 
¼ ED50 2.8 
½ ED50 5.5 
ED50 11 
2 ED50 22 
 
SP600125 (SP) 
ED50 status Concentration (µM) 
¼ ED50 50 
½ ED50 100 
ED50 200 
 
7F + SP 
ED50 status Combination Index (CI) 
¼ ED50 7F + ¼ ED50 SP 2.1 
¼ ED50 7F + ½ ED50 SP 2.4 
¼ ED50 7F + ED50 SP 2.1 
½ ED50 7F + ¼ ED50 SP 1 
½ ED50 7F + ½ ED50 SP 1 
½ ED50 7F + 1 ED50 SP 0.6 
ED50 7F + ¼ ED50 SP 0.4 
ED50 7F + ½ ED50 SP 0.3 
ED50 7F + ED50 SP 0.6 
2 ED50 7F + ¼ ED50 SP 0.2 
2 ED50 7F + ½ ED50 SP 0.3 
2 ED50 7F + ED50 SP 0.6 
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Satisfied with the cytotoxicity of 7-formyl-10-methylisoellipticine in vitro, we 
moved our compound into an in vivo model. To evaluate in vivo toxicity mice were 
i.p. injected with 7-formyl-10-methylisoellipticine at a range of doses. Results 
demonstrated that 7-formyl-10-methylisoellipticine does not cause a change in body 
weight at any of the given doses (Figure 5.7).  
 
 
 
 
 
 
Figure 5.6. 7-Formyl-10-methylisoellipticine has synergistic effects when used in 
combination with diphenyleneiodonium (DPI). ED50 values were determined using the 
trypan blue exclusion assay following treatment of MV4-11 cells for 24 hours with the 
compounds. The combination index (CI) at various dose effects was calculated using the 
median effect method. CI values less than 1 indicate synergy; CI of 1 indicates an additive 
effect; and CI greater than 1 demonstrates antagonism between the 2 agents. 
7-Formyl-10-methylisoellipticine (7F)  
ED50 status Concentration (µM) 
¼ ED50 2.8 
½ ED50 5.5 
ED50 11 
2 ED50 22 
 
Diphenyleneiodonium (DPI) 
ED50 status Concentration (µM) 
¼ ED50 12.25 
½ ED50 25 
ED50 50 
 
7F + DPI 
ED50 status Combination Index (CI) 
¼ ED50 7F + ¼ ED50 DPI 0.002 
¼ ED50 7F + ½ ED50 DPI 0.004 
¼ ED50 7F + ED50 DPI 0.007 
½ ED50 7F + ¼ ED50 DPI 0.004 
½ ED50 7F + ½ ED50 DPI 0.005 
½ ED50 7F + 1 ED50 DPI 0.009 
ED50 7F + ¼ ED50 DPI 0.006 
ED50 7F + ½ ED50 DPI 0.008 
ED50 7F + ED50 DPI 0.248 
2 ED50 7F + ¼ ED50 DPI 0.920 
2 ED50 7F + ½ ED50 DPI 0.843 
2 ED50 7F + ED50 DPI 0.586 
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Another indication that the compound was not toxic to these animals was that 
no significant difference in terms of cell morphology and tissue structure was 
observed in mice with or without treatment of the compound (Figure 5.8). All of this 
evidence suggests that 7-formyl-10-methylisoellipticine does not cause systemic 
toxicity. While it may be a positive characteristic of a chemotherapeutic not to cause 
toxicity in this model, we were concerned that firstly, a higher dose was needed and 
secondly, that the DMSO solvent was not a good enough vehicle in the animal model. 
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Figure 5.7. 7-Formyl-10-methylisoellipticine dissolved in 100% DMSO is not toxic to 
BALB/c mice at the given doses. Graph shows the mean mouse body weight derived from 
five individual mice in response to treatment with control or the indicated dose of 7-
formyl-10-methylisoellipticine. Results are expressed as means. Error bars show the SEM. * 
= p-value <0.001 
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When redesigning this toxicity study we employed an alternative solvent in 
the form of polyethylene glycol (PEG). PEG is substantially used as a 
pharmaceutically accepted solvent for chemotherapeutics (Solanki et al, 2013). 
Therefore, the compound was prepared using a PEG 400-water co-solvent (30% PEG 
Figure 5.8 7-Formyl-10-methylisoellipticine dissolved in 100% DMSO does not show 
signs of toxicity in the organs of BALB/c mice. The lung, spleen, brain, heart, liver and 
kidney BALB/c mice treated with the control or the indicated dose of 7-formyl-10-
methylisoellipticine to observe cell morphology and tissue structure (x40).  
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400, volume/volume). We demonstrated that when the compound is dissolved in this 
solvent it has a similar in vitro anti-proliferative effect as observed by the compound 
dissolved in DMSO (Figure 5.9), indicating that this cosolvent is suitable for 
administration of 7-formyl-10-methylisoellipticine and was used for the successive in 
vivo studies.  
 
 
 
 
 
 
 
 
 
 
We proceeded to study the toxicity of 7-formyl-10-methylisoellipticine in a 
similar manner to before. This time however, as well as using 5 mg/kg and 10 mg/kg 
treatments of the compound, we also used higher doses of 25 mg/kg and 50 mg/kg. 
The increased doses were included as the doses used in the previous experiment 
(Figure 5.7) did not produce a cytotoxic effect and we sought a dose that would 
ultimately have anti-tumour properties in a therapeutic model.  
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Figure 5.9. PEG solvent mixture has similar toxicity profile to DMSO in vitro. The 
effects of a range of doses of 7-formyl-10-methylisoellipticine dissolved in either 100% 
DMSO or a solution of 30% polyethylene glycol, 70% H2O and < 1% DMSO on MV4-11 
cells treated for 24 hours. Toxicity was measured by propidium iodide staining. The error 
bars represent ±SD. n = 9.  
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Figure 5.10 shows that 7-formyl-10-methylisoellipticine is not toxic at any of 
the given doses, even 50 mg/kg. In addition, the treatment of 7-formyl-
methylisoellipticine did not significantly (P > 0.05) increase levels of alanine 
aminotransferase (ALT) and aspartate aminotrandferase (AST), markers of liver 
damage, relative to negative control (Figure 5.11). 
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Figure 5.10. 7-Formyl-10-methylisoellipticine dissolved in PEG solvent (30% 
polyethylene glycol, 70% H2O and < 1% DMSO) is not toxic to BALB/c mice at the 
given doses. Graph shows the mean mouse body weight derived from five individual mice in 
response to treatment with control or the indicated dose of 7-formyl-10-methylisoellipticine. 
Results are expressed as means. Error bars show the SEM. * = p-value <0.001 
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Figure 5.12 7-Formyl-10-methylisoellipticine does not damage the liver of BALB/c mice. 
Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) activity in the serum 
of mice in response to treatment with control or the indicated dose of 7-formyl-10-
methylisoellipticine. Results are expressed as means. Error bars show the SEM.  
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As with the DMSO solvent, staining with H&E showed no significant 
difference in terms of cell morphology and tissue structure in mice with or without 
treatment of the compound dissolved in PEG cosolvent (Figure 5.12). All of this 
evidence suggests that 7-formyl-10-methylisoellipticine does not cause systemic 
toxicity. 
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Figure 5.12. 7-Formyl-10-methylisoellipticine dissolved in PEG solvent (30% 
polyethylene glycol, 70% H2O and < 1% DMSO) does not show signs of toxicity in the 
organs of BALB/c mice. The lung, spleen, brain, heart, liver and kidney BALB/c mice 
treated with the control or the indicated does of 7-formyl-10-methylisoellipticine to observe 
cell morphology and tissue structure (x40).  
Figure 5.11. 7-Formyl-10-methylisoellipticine dissolved in PEG solvent (30% 
polyethylene glycol, 70% H2O and < 1% DMSO) does t show signs of toxicity in the 
rgans of BALB/c mice. The lung, spleen, brain, heart, er and kidney BALB/c mice 
treated with the control or the indicated dose of 7-formyl-10- ethylisoellipticine to observe 
cell morphology and tissue structure (x40).  
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 Although the 50 mg/kg dose was well tolerated (Figure 5.10), we used 
25 mg/kg in the therapeutic study based on the literature available regarding 
structurally similar compounds (Peng et al, 2003) (Prudent et al, 2010). An AML 
xenograft mouse model was used to determine the therapeutic effect of 7-formyl-10-
methylisoellipticine (Figure 5.1). Our results showed that 7-formyl-10-
methylisoellipticine significantly slowed down the tumour growth, approximately 4 
fold relative to the control group at the end point of the experiment  (p value < 0.001) 
(Figure 5.13).  
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Figure 5.13. 7-Formyl-10-methylisoellipticine has anti-tumour activity in SCID mice 
bearing xenograft tumour. A. Photograph of tumours dissected from mice treated with 
either the control or 25 mg/kg 7-formyl-10-methylisoellipticine. B. Volume of tumour in 
SCID mice bearing xenograft tumour in response to treatment with control or the 25 mg/kg 
7-formyl-10-methylisoellipticine. Error bars show the SEM. * = p-value <0.001  
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In addition to this decrease in tumour volume, Figure 5.14 reiterates the 
decrease in tumour size by showing that 7-formyl-10-methylisoellipticine 
significantly reduces tumour mass, up to 7-time reduction relative to the control. 
 
 
 
 
 
 
 
 
 
We also stained tumours dissected from mice treated with the control and the 
7-formyl-10-methylisoellipticine respectively, to observe if there were any gross 
morphological differences between the two. However, no noticeable discrepancies 
were seen (Figure 5.15).   
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Figure 5.14. 7-Formyl-10-methylisoellipticine reduces tumour mass in SCID mice 
bearing xenograft tumour. Normalised tumour weight in SCID mice bearing xenograft 
tumour in response to treatment with control or 25 mg/kg 7-formyl-10-methylisoellipticine. 
Results are expressed as means derived from eight individual mice in each of the two groups 
on the final day of the experiment. Error bars show the SEM. * = p-value <0.001  
Control 25 mg/kg 
Figure 5.15. 7-Formyl-10-methylisoellipticine does not cause morphological changes to 
xenograft tumous dissected from SCID mice. Tumours were extracted from SCID mice 
treated with either control or 25 mg/kg 7-formyl-10-methylisoellipticine and stained with 
hematoxylin and eosin to observe cell morphology and tissue structure (x40).  
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Discussion: 
As chemotherapy drugs are frequently more effective when given in 
combination, a compound that can act in sync with other agents is desirable. We 
examined the cytotoxicity of 7-formyl-10-methylisoellipticine when administered 
simultaneously with other agents. The results obtained from these experiments were 
not only indicative of whether our compound may have clinical potential but also 
served to reveal information regarding the compounds mechanism of action.  
 The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay is a well-established test for measuring cell viability, proliferation of cells, and 
cytotoxicity of new drug candidates (Liu et al, 1997). This is a quantitative 
colorimetric assay, where living cells reduce the yellow tetrazolium salt MTT to blue 
formazan crystals (Mosmann, 1983). Advantages of this assay are that it is widely 
used and inexpensive. Therefore, this was our initial assay of choice for measuring the 
cytotoxic effects of the drug combinations. However, it became apparent that this 
assay was not sensitive enough for our experiments. For example, when measuring 
the cell death induced by 7-formyl-10-methylisoellipticine, clear changes were 
observed between concentrations of 10 μM and 50 μM, yet little difference was seen 
between doses of 1 μM, 5 μM and 10 μM (data not shown). This lack of sensitivity is 
acknowledged by the manufacturers (Promega) and has been studied by several 
groups (Jaszczyszyn & Gasiorowski, 2008) (Wang et al, 2010) (Wang et al, 2011b). It 
has been suggested that the inaccuracy of results may be due to compounds directly 
interacting with MTT (Ulukaya et al, 2008) or reduction of MTT by superoxide 
(Wang et al, 2011b). Although the trypan blue assay is the most time-consuming of 
the tests mentioned, it is a robust assay, which involves visualisation of the cells, and 
therefore was used as the principle analysis of cytotoxicity. Significant results were 
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validated by cell cycle analysis for further confirmation. 
7-Formyl-10-methylisoellipticine has antagonistic effects when used in 
combination with Ara-C (Figure 5.2). This was disappointing as Ara-C is the main 
drug used in AML induction therapy. However, like Ara-C, 7-Formyl-10-
methylisoellipticine did have synergistic effects with daunorubicin (Figure 5.3).  This 
may be of importance when conducting future in vivo experiments. 
In the previous chapter we concluded that 7-formyl-10-methylisoellipticine 
functions partially through increasing ROS. We hypothesised that if the compound 
needs to produce ROS to exert its effects, then an antioxidant should diminish its 
cytotoxicity. We selected butylated hydroxyanisole as the antioxidant to use in 
combination as it is widely used for its antioxidant properties (Singh et al, 2013). Our 
results showed that these two compounds have mainly additive or antagonistic effects 
except when both of them are used above their ED50 concentrations (Figure 5.4). 
This again reinforces that isoellipticines cytotoxicity depends on their ability to 
stimulate the production of ROS. However, it is worth noting that skepticism 
surrounds the use of antioxidants for the treatment of cancer and many other diseases 
(Melton, 2006). 
In chapter 4 we established that 7-formyl-10-methylisoellipticine activates 
JNK. To investigate this further we used 7-formyl-10-methylisoellipticine in 
combination with SP600125, a JNK inhibitor.  Our results showed that once the two 
compounds are used above their ED50, they had antagonistic effects (Figure 5.5). 
This indicates that while 7-formyl-10-methylisoellipticine can activate the JNK 
pathway, it is not essential for its cytotoxic effect. 
The final drug that we used in combination was the Nox inhibitor, 
diphenyleneiodonium (DPI). Synergy between these two agents was demonstrated at 
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a preliminary level in chapter 4. However, that study involved a pre-treatment with 
DPI before the addition of 7-formyl-10-methylisoellipticine, whereas here, the two 
agents were given simultaneously. Furthermore, the doses of DPI used in the previous 
study aimed to inhibit ROS production and not kill the cells, therefore the 
concentrations used did not even reach ¼ ED50. Here, we conducted a more thorough 
investigation of the effect of DPI when used in combination with 7-formyl-10-
methylisoellipticine on MV4-11 cells. Initially, to study Nox inhibition we aimed to 
use VAS2870, as this inhibitor is known to be more specific than DPI (Hole et al, 
2011). However, to kill MV4-11 cells VAS2870 had to be used at concentrations too 
high to control for. Therefore we continued to use DPI. Our study revealed that DPI 
and 7-formyl-10-methylisoellipticine had strong synergy (Figure 5.6). A CI value of 
less than one was calculated for every single dose combination. This synergy suggests 
that the MV4-11 need fully functioning Nox to survive. Similar to SP600125, this is 
not only interesting from a clinical point of view but also from a chemotherapeutic 
perspective as DPI is being investigated for its use in CML (Sanchez-Sanchez et al, 
2014). 
Although ellipticines display a lack of hematological toxicity (Auclair, 1987), 
they still caused unexpected toxic side effects (Miller et al, 2012). In this study, the in 
vivo toxicity analysis of 7-formyl-10-methylisoellipticine indicates that the compound 
did not cause significant signs of toxicity in terms of animal body weights, the liver 
enzymes and the histology of major organs (Figure 5.7-5.12). Although a dose of 25 
mg/kg was utilised in the current work, it is worth noting that 50 mg/kg was not toxic 
to the mice and therefore this higher dose could potentially be used in future studies.  
  Consistent with in vitro anti-proliferative effects, 7-formyl-10-
methylisoellipticine displayed promising anti-tumour activity in an AML xenograft 
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model (Figure 5.13-5.14). This study did not however elucidate the mechanism of 7-
formyl-10-methylisoellipticine in vivo. This is an aim, which hopefully future studies 
will achieve. Furthermore, although the given dose did significantly impede the 
growth of the tumour throughout the experiment, it did not completely eradicate the 
tumour (Figure 5.13). To completely eradicate the tumour it may be necessary to 
design a regimen that combines 7-formyl-10-methylisoellipticine with another drug, 
for example daunorubicin. The information obtained from the combination 
experiments in this study could potentially be used to design such a regimen.
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Dr. Sidney Farber discovered aminopterin, the first effective leukaemia 
treatment in the 1940s. Since then, leukaemia has had one of the richest histories in 
cancer care. The discovery of chromosomes 9 and 22 translocating and subsequent 
targeting with imatinib, have led to chronic myeloid leukaemia being viewed as a 
paradigm in cancer care. Other notable milestones in leukaemia research include; the 
use of combination therapy since 1958, and the appreciation of leukaemic stem cells. 
All of these concepts are relevant to a broad range of cancers. As such, leukaemia 
research acts as a useful tool to extend survival of many different forms of cancer. 
 Despite the historic success of AML treatment, only 25 – 45% of AML 
patients have long-term leukaemia survival. These data support the understanding that 
the disease results from the accumulation of a number of molecular events that 
deregulate signalling pathways, leading to diseases that are more resistant to 
traditional cancer therapies. Therefore, new treatments are needed for leukaemia 
patients, particularly those with unfavourable risk factors (Ravandi, 2012). 
Comprehension of the multistep development of tumours will contribute to the 
development of new means to treat cancer. In order for a tumour to develop, it must 
have certain biological capabilities. These hallmarks include sustaining proliferative 
signal, evading growth suppressors, resisting cell death, enabling replicative 
immortality, inducing angiogenesis, and activating invasion and metastasis (Hanahan 
& Weinberg, 2000). Of these, potentially the most fundamental trait of cancer cells is 
their ability to sustain chronic proliferation. Normal tissues manage the production 
and release of growth-signals that control progression through the cell cycle, therefore 
ensuring homeostasis and function. Cancer cells deregulate these signals. 
Unfortunately, the identities and sources of proliferative signals operating within 
normal tissues are poorly understood (Hanahan & Weinberg, 2011).  The mitogenic-
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signalling in cancer cells is relatively better understood but there is still much to be 
learned (Lemmon & Schlessinger, 2010). A clearer understanding of the signalling 
that occurs in normal and cancer cells would benefit the development of 
chemotherapeutics. For example, when studying the effects of 7-formyl-10-
methylisoellipticine on certain kinases in Chapter 4, it was difficult to establish the 
significance of the compound-induced changes, as the role of these kinases in 
proliferation still needs to be fully elucidated.    
 Autophagy, a key player in therapeutic stress, is another phenomenon that 
needs to be investigated further to enhance drug development. Autophagy is an 
important cell-physiologic response that mediates both tumour cell survival and death 
(Kroemar & Levine, 2008). This process enables cells to break down cellular 
organelles, resulting in the catabolites being recycled. Nutrient starvation and certain 
cytotoxic drugs can induce elevated levels of autophagy that are cytoprotective for 
cancer cells (White & DiPaulo, 2009). Paradoxically, autophagy also induces cell 
death. Influential research has revealed connections between circuits controlling 
autophagy, apoptosis and cellular homeostasis. The PI3K/AKT/mTOR pathway is 
stimulated by survival pathways and therefore blocks apoptosis and also inhibits 
autophagy. In a similar fashion, if survival signals are insufficient, this pathway is 
down regulated and autophagy and/or apoptosis may be induced (Levine et al, 2008). 
It can be seen in this study that it is problematic to explain the effects of a drug on 
autophagy (Figure 4.3). A complete understanding of the role of autophagy in cancer 
cells is needed so that the implications of a chemicals effect on this process can be 
analysed. Autophagy research will be vital to chemotherapeutic development, as 
targeting autophagy has recently been shown to reduce drug resistance (Sui et al, 
2013).  
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 Just as autophagy research is contributing to the study of cancer, growing 
appreciation for the concept of genomic instability is also improving treatment. 
Genomic instability refers to a high frequency of mutations within the genome of a 
cellular lineage (Schmitt et al, 2012). Tumour cells must acquire some form of 
genomic instability for oncogenic transformation to occur (Sieber et al, 2003). ROS, 
due to their DNA damaging properties, contribute to genomic instability (Hole et al, 
2011). Different oncogenes have been shown to induce a higher level of ROS and 
genomic instability. Stanicka et al. showed that FLT3-ITD, which allows constitutive 
activation of the receptor, increases Nox and p22phox protein levels that generate 
H2O2 at the nuclear membrane (Stanicka et al, 2015). Furthermore, this report 
demonstrated that Nox knockdown caused a decrease in H2O2 and subsequent DNA 
damage. MV4-11 cells are homozygous for the FLT3-ITD mutation. This may 
explain why synergy results from the combination of 7-formyl-10-methylisoelipticine 
with DPI, a Nox inhibitor. 7-Formyl-10-methylisoellipticine increases mitochondrial 
ROS, which is known to induce apoptosis (McManus et al, 2014) while DPI inhibits 
Nox, which produce ROS that are needed for cell survival (Stanicka et al, 2015). It is 
likely that the contrasting mechanisms of these compounds promote the synergy. 
Future combination studies with 7-formyl-10-methylisoellipticine could potentially 
use a specific FLT3-ITD inhibitor. For example, quizartinib (AC220), a FLT3-ITD 
inhibitor has been shown in a phase I trial to be safe and efficacious in patients 
(Cortes et al, 2013). 
As AML is such a heterogeneous disease, it seems appropriate that a 
compound that affects such as ellipticine, which affects a vast array of targets, inhibits 
its growth. Almost every year since the turning of the millennium, a new mechanism 
of this drug has been discovered. As well as interacting with DNA and inhibiting 
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kinases, ellipticines also interact with p53, cause mitochondrial damage, induce ER 
stress and increase ROS production. Despite historic validity in solid tumours 
(Stiborova et al, 2010) it was in leukaemia cell lines which isoellipticines 
demonstrated the greatest level of inhibition against in a NCI 60-cell screen (Miller et 
al, 2012). It was originally hypothesised that isoellipticines were efficient at inhibiting 
the growth of leukaemia cell lines due to their ability to inhibit topoisomerase, as 
many successful chemotherapeutics, such as etoposide function in this way (Baldwin 
et al, 2005). It is therefore curious to note that topoisomerase II appears not to be the 
most important biological target with respect to anti-cancer activity of isoellipticines 
(Miller et al, 2012). This highlights the need to uncover the fundamental 
mechanism(s) of action of this compound class, which this study has contributed to. It 
also suggests that isoellipticine may be beneficial for treating leukaemia in a clinical 
setting as recently topoisomerase inhibitors have been shown to actually induce 
leukaemia (Pendleton et al, 2014). 
 Recent research has concentrated on the delivery of ellipticine. It has been 
found that supramolecular polymer conjugate is a good candidate for the delivery of 
ellipticine-based drugs (Studenovsky et al, 2015). Furthermore, Sedlacek et al. have 
described an optimised triple-targeted polymer delivery system for ellipticine, which 
contains radioisotope iodine-125 with high specific radioactivity (Sedlacek et al, 
2015). Indeed from the beginning to the end of this study we changed solvent from 
the more conventional DMSO to PEG 400-water co-solvent (30% PEG 400, 
volume/volume). We demonstrated that when the compound is dissolved in this 
solvent it has a similar in vitro anti-proliferative effect as observed by the compound 
dissolved in DMSO (Figure 5.9). However, it is known that this co-solvent is better 
tolerated than DMSO in vivo (Maes et al, 2012). The transition to this solvent is a 
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good example of how the research in this study can be integrated with research from 
other disciplines.         
 Current AML therapeutics are simply not efficient enough. With respect to 
this I aimed to study the effects of isoellipticines, a novel compound class, on 
leukaemia cell lines and to probe their mechanism of action. Although many aspects 
of isoellipticines remain a mystery, key functions of these compound were discovered 
in this study.           
 It was unknown at the time of synthesis if these compounds would all have the 
same, if any effect on MV4-11 cells. I showed that the nine novel compounds had 
distinct effects on the cell cycle. Compounds 1 and 2 caused a G2/M arrest. 
Compounds 3-5 increased sub G1 phase while compounds 6-9 had no effect on the 
cell cycle at the given dose. In order for a cell to divide successfully, it must undergo 
each phase of the cell cycle. The machinery controlling the mammalian cell cycle 
consists of cdks, which are activated by association with cyclin regulatory subunits. 
Targeted cancer therapies aim to interrupt a specific component of the complex 
signalling pathways that result in uncontrolled cell proliferation (Aleem & Arceci, 
2015). The knowledge specific components of the cell cycle apparatus that 
isoellipticines disrupt may be beneficial for designing more targeted therapy. I also 
concluded that isoellipticines kill MV4-11 cells by apoptosis. Although as explained 
above, isoellipticines and indeed the effect of numerous drugs on apoptosis/autophagy 
may be worth revisiting when a deeper understanding of autophagy is gained. In 
addition to isoellipticines cytotoxic effects, I showed that the 9 compounds all 
infiltrate the cells to different extents and fluoresce at different intensities. This 
knowledge will be beneficial in designing future studies as the compounds with 
cytotoxic potential are now identified and suitable assays can be selected based on 
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their fluorecence.        
 One of the most substantial revelations of this study was the increase in ROS 
that isoellipticines produce (Russell et al, 2014) (Russell et al, 2015).  Many mainstay 
cancer therapies, such as daunorubicin may rely on their ability to increase ROS to 
exert their full cytotoxic effect (Mansat-de Mas, 1999). This is possible as the highly 
stressed state of malignant cells may partly explain the selectivity of these cytotoxic 
drugs (Benhar et al, 2002). Several compounds with pro-oxidant capacity appear to be 
effective against both leukaemic cell lines and primary leukaemic blasts (Hole et al, 
2011). It was of great interest that 7-formyl-10-methylisoellipticine induced 
mitochondrial derived ROS. This will allow optimum design of combination 
experiments, such as that involving 7-formyl-10-methylisoellipticine and DPI. The 
full role of ROS in carcinogenesis remains unknown. Therefore studies like this, 
which show the source of the ROS produced by a cytotoxic agent, may contribute to 
the wider understanding about ROS mechanism. We also reported that this increase in 
ROS induces the DNA damage response pathway, including the increase in 
expression of p53. The effect of compounds on p53 is relevant as there is a correlation 
between p53 mutations and chemotherapy resistance (Soussi, 2003).
 Combination therapy is an attractive regimen as it can increase cytotoxicity, 
reduce side effects and decrease resistance. The results obtained from our 
combination experiments were not only indicative of whether our compound may 
have clinical potential but also served to reveal information regarding the compounds 
mechanism of action. The lack of synergy seen between 7-formyl-10-
methylisoellipticine and Ara-C suggests that the compounds may function in the same 
way. Furthermore, combinations with the JNK inhibitor, SP600125 and butylated 
hydroxyanisole respectively, reveal that ROS production is essential for 7-formyl-10-
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methylisoellipticines cytotoxicity, while activation of the JNK pathway is not. 
However, probably the most interesting results observed from the combination study 
are the synergistic effects seen between 7-formyl-10-methylisoellipticine and both 
daunorubicin and DPI respectively. These results may be of clinical relevance and so 
should be investigated further. Unfortunately, these experiments did have limitations. 
The first of these is that the trypan blue exclusion assay is laborious and can be 
viewed as biased. To overcome this, blinded experiments were used when possible. 
However, moving forward it would be beneficial to optimise a more high-throughput 
assay. The second limitation is that the effects were only examined when the drugs 
were administered simultaneously. It would be interesting to examine the effects of 
different permutations. Nonetheless, the data generated from these experiments is 
useful preliminary research.  
Arguably the most significant results of the study were the anti-tumour effects 
of 7-formyl-10-methylisoellipticine in an AML cell-derived xenograft (CDX) model 
(Figure 5.13-5.14). These results are enhanced by the observation that the compound 
did not cause significant signs of toxicity in terms of animal body weights, the liver 
enzymes and the histology of major organs (Figure 5.7-5.12). Taken together these 
data suggest that 7-formyl-10-methylisoellipticine may display clinical potential. It is 
worth noting that the mechanism of the compound in vivo has not been elucidated in 
this study. Consistent with the in vitro data on the compound, I examined protein 
expression in the tumours of caspase 3 and PARP but no change was seen in either. 
Upon examination of the H&E stain of the tumour section, it appeared in the tumours 
treated with 7-formyl-10-methylisoellipticine had less blood vessels. However, 
western blot analysis using a VEGF antibody showed that this was not the case. 
Furthermore, western blots were carried out with tumour lysates and probed for cyclin 
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B1 and γH2AX. However, these proteins could not be detected. The anti-tumour 
effects of 7-formyl-10-methylisoellipticine are impressive but the mechanism of 
action of this compound will need to be recognised for it to be truly effective.  
 Using this study as a foundation, there are many directions that research on the 
impact of isoellipticines on leukaemia could take. Fundamental research using cancer 
cell lines to investigate isoellipticine mechanism of action will provide data that will 
be crucial when examining the compounds in more advanced systms. In BALB/c 
mice, at a concentration of 50 mg/kg, 7-formyl-10-methylisoellipticine was not toxic. 
Therefore, this concentration could be tested in future work with the aim of 
eradicating and not just reducing tumour volume. It would be insightful to examine 
the effect of 7-formyl-10-methylisoellipticine and indeed other isoellipticines, on a 
more advanced mouse model of leukaemia. Such models include orthotopic AML 
patient-derived xenograft (PDX) models (Vick et al, 2015). While undoubtedly, 
animal models are invaluable tools in leukaemia research, the use of biospecimens in 
a study such as this could provide vast volumes of information. Historically, 
leukaemia research surpassed the investigation of other cancers due to the ease of 
extracting a blood sample relative to removing a solid tumour. This unique 
characteristic should still be taken advantage of.       
 The biggest success story of leukaemia research in recent decades was the 
approval of imatinib (Gleevec). This drug targets the ‘Philidelphia chromosome’, 
which researchers discovered causes CML in the 1960s. However, AML is a much 
more aggressive, heterogeneous and multigene disease than CML (Fabbro & 
McCormick, 2005). Therefore, it is unlikely that the same ‘magic bullet’ therapy will 
be applied to treat AML. In reality, it is more probable that an array of drugs with 
distinct mechanisms will be used to combat this disease. These drugs will be designed 
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based on the knowledge gained from fundamental biological research, genetic studies, 
pharmacokinetic investigations and of course serendipity. While translating new 
knowledge into better cancer diagnostics and treatments will bring with it new 
challenges (Johnson & Lawler, 2012), it is likely that eradicating leukaemia will be an 
interdisciplinary effort. Of course, thinking logically, the disease should be 
completely understood before one begins to tackle it. However, time is of the essence. 
With approximately 25,000 people dying every year from leukaemia (www.lls.org), 
researchers can’t delay in designing new therapies.  
       Ellipticine has been the focus of extensive pharmacological research due 
to the discovery of its anti-tumour effects. Isoellipticines represent a novel compound 
class, which retain these anti-tumour properties while evading side effects. In this 
study, we have showed that 7-formyl-10-methylisoellipticine has a potent cytotoxic 
effect on leukaemia cells, which is at least partially mediated by the induction of 
ROS. Furthermore, our study documents for the first time the therapeutic potential of 
an isoellipticine compound in a subcutaneous AML cell-derived xenograft (CDX) 
model. By further investigation of isoellipticine mechanism of action and employing 
more advanced disease model, I believe an ellipticine analogue with clinical 
application may be developed. 
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